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 1. INTRODUCTION 
 S-adenosylmethionine (abbreviated AdoMet or SAM) is the main methyl donor for the 
multitude of transmethylation reactions that take place in all organisms. The trivalent bonding  of 
its cationinc sulfur atom, however, also allows donation of two other groups, hence broadening 
the catalogue of reactions in which AdoMet participates; amongst these are decarboxylation 
followed by propylamine donation in polyamine biosynthesis, and reductive cleavage of the 
bond between the sulfur and the ribosyl carbon to yield the 5!-deoxyadenosyl radical which is 
catalyzed by radical SAM proteins (see Figure 1A) [1, 2]. It has been estimated that AdoMet 
participates in as many reactions as ATP. In contrast AdoMet can be synthesized only through 
the process catalyzed by methionine adenosyltransferase (MAT also called S-
adenosylmethionine synthetase; E.C. 2.5.1.6) in the reaction shown in Figure 1B. The MAT 
family of enzymes has been shown to be present in all cell types through archaea, bacteria and 
eucarya, except for a few obligatory parasites [3]. Moreover, a high level of sequence 
conservation exists between bacterial and eukaryotic MATs, whereas archaea express a distinct 
class of MAT. In all the cases the preferred quaternary structure is an oligomer, at least a dimer. 
Amongst MATs, the E. coli (cMAT) and mammalian MATs (MAT I/III and MAT II) are the most 
studied, hence most of the reported structural and regulatory data have been obtained from 
these proteins. 
 MAT catalysis of AdoMet synthesis is the rate limiting step of the methionine cycle 
(Figure 2). The use of AdoMet in transmethylation reactions leads to production of S-
adenosylhomocysteine (AdoHcy), which is a potent inhibitor of methyltransferases. AdoHcy is 
typically metabolized by S-adenosylhomocysteine hydrolase (SAHH), in a reversible reaction 
that favors resynthesis of AdoHcy. Thus, homocysteine (Hcy) and adenosine, the products of 
AdoHcy hydrolysis, have to be eliminated in a coordinated manner in order to avoid 
accumulation of the transmethylation inhibitor, which would lead to a reduction in the 
methylation index (the AdoMet/AdoHcy ratio). Adenosine is removed by adenosine deaminase 
catalyzed conversion to inosine, whereas Hcy is consumed in several processes, which vary 
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amongst tissues and organisms. In mammalian liver, three are three reactions involved in Hcy 
utilization, thus making a branch point in the cycle. These are: i) synthesis of cystathionine by 
cystathionine-"-synthase (CBS), which initiates the trans-sulfuration pathway; ii) remethylation 
of Hcy, catalyzed either by methionine synthase (MS) or betaine homocysteine 
methyltransferase (BHMT); and iii) Hcy exportation to the plasma. Remethylation reactions allow 
recovery of methionine for AdoMet resynthesis, thus playing an important role when there are 
low levels of this amino acid. Moreover, MS links the methionine cycle to the folate cycle, and 
BHMT allows recovery of one of the methylation equivalents used for choline synthesis. On the 
other hand, export to the plasma and CBS catalyzed entrance in the trans-sulfuration pathway 
allows elimination of excess Hcy, and in the last case cysteine is formed that can be used for 
protein and glutathione (GSH) production. The flux through the cycle is modulated at different 
levels by some of the metabolites mentioned above; see previous reviews such as [4]. 
 The last decade has produced a large increase in the understanding of the structural, 
functional and regulatory properties of MATs, including the elucidation of the three dimensional 
structures of several of these enzymes and unexpected findings on evolutionary conservation 
and diversity. This review of the MAT family of enzymes attempts a complete overview of the 
achievements of the last decade. Lastly, important new results relating MAT function to the 
development of certain diseases are also discussed. 
 
 2. MAMMALIAN MATs 
 Early studies on mammalian MATs showed the existence of this activity in all the tissues 
studied, the highest being observed in liver. However, complex kinetics were obtained which 
made the results difficult to interpret until the presence of several isoenzymes was realized. 
Separations carried out on phenyl Sepharose columns showed elution of three peaks with 
different hydrophobic character; these were named according to the order of elution as MAT I, II 
and III. All these isoenzymes share some characteristics such as the Mg2+ dependence of their 
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activity (S0.5 !1 mM), stimulation by K
+ ions, and their AdoMet-inducible tripolyphosphatase 
activity [4, 5]. 
 
2.1. MAT I/III isoenzymes 
 Since their discovery, these isoenzymes were known as liver-specific forms of MAT, until 
Lu et al. in 2003 [6] showed their presence also in pancreas.  Several laboratories have reported 
in depth studies of MAT I and III which have been carried out using adult liver.  The differences 
can be summarized as follows: i) MAT I is a tetramer whereas MAT III is a dimer, with 
respective Mr appearing as 200 and 110 kDa upon gel filtration chromatography, ii) their Km 
values for methionine are in the micromolar range for MAT I (60-120 µM) and in the millimolar 
range for MAT III (1 mM) [7, 8]; iii) MAT III can be activated by DMSO at physiological 
concentrations of methionine (60 µM) and is highly hydrophobic (eluting from phenyl Sepharose 
columns at 50% DMSO (v/v)); and, iv) AdoMet inhibits MAT I and activates MAT III. Some of 
these differences are normally used to distinguish between isoenzymes in activity assays. Both 
purified proteins show a common single band (designated "1) of approximately 48 kDa on SDS-
PAGE, and antibodies raised against the dimer form recognized both, thus suggesting that a 
single type of subunit arranged in two assemblies could explain the presence of both oligomers 
[7]. Further experiments that supported this hypothesis included peptide mapping of the purified 
isoenzymes [7], dissociation of the tetramer to the dimer using LiBr [9] or N-ethylmaleimide 
(NEM) modification [10]. The final confirmation came upon cloning of a single cDNA [11, 12] 
followed by overexpresion in E. coli cells [13], which showed in vivo production of dimers and 
tetramers. This single subunit type is a product of the MAT1A gene that contains nine exons 
and eight introns spanning !20 kb [14], and has been localized by fluorescence in situ 
hybridization to the human chromosome 10q.22 [15].  
 Animal models, as well as the analysis of human samples, led to the identification of 
changes in the MAT I/III ratio in pathological conditions [16], which has stimulated interest in the 
mechanisms that regulate this interconversion. Several in vitro approaches have indicated the 
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importance that cysteine residues have both in the regulation of the association state, and in 
controlling their activity [8, 17-19]. N-ethylmaleimide (NEM) modification of two 
sulfhydryls/subunit leads to inactivation and dissociation of the tetramer to inactive dimers [10]. 
Moreover, only 7-8 out of the 10 cysteines present in each subunit were modified by either NEM 
or nitric oxide (NO), even after denaturation [20, 21], but denaturation in the presence of DTT 
allowed full labeling of the sulfhydryl groups [22]. These observations along with data on SDS-
PAGE mobility changes after thiopropyl Sepaharose chromatography, and the mechanisms of 
GSH/GSSG regulation involving the production of an intrasubunit disulfide [8], prompted deeper 
study of the oxidation state of MAT I/III cysteines. Thus, the presence of a disulfide bond linking 
C35 and C61 within a subunit was identified [22]. Once available, the MAT I crystal structure 
showed that these residues are the only cysteines properly oriented, and at distance suitable for 
formation of an intrasubunit disulfide bridge [23]. Although it is not common for a cytosolic 
protein to contain a disulfide, examples exist, and their formation is highly dependent on a 
protein conformation that provides a high local concentration of sulfhydryls to allow formation of 
the disulfide even in the highly reducing environment of the cytosol [24]. The role of this disulfide 
in MAT I/III stability is discussed in the Folding section (10, below).  In addition, site directed 
mutagenesis studies demonstrated that changes of any of the cysteines located between 
residues 35 and 105 modify the MAT I/III ratio; most interesting was the C69S mutant which 
appears mainly as dimers [19]. Within this region, C121 was found to be of great importance for 
control of activity, as deduced from the experiments using NO and hydrogen peroxide that are 
discussed in the MAT regulation Section (2.3, below). 
 Early estimates of MAT I/III subunit size obtained by SDS-PAGE indicated molecular 
weights of 48 kDa for the "1 subunit [7]. This value was higher than the theoretical size 
calculated from the sequence, and which led several authors to suggest post-translational 
modifications as responsible for these differences. Examination of the sequence revealed the 
presence of putative phosphorylation sites for several kinases, but only the case of PKC has 
been explored in vitro [25]. Incorporation of 32P-phosphate onto threonine-342, the most 
 9/14/2012             Page 8 of 80 
exposed residue according to hydrophobicity profiles, was obtained mainly in the dimer with a 
concomitant delay in its elution on gel filtration chromatography. These results suggested that 
MAT III is a partially phosphorylated form, and implied that complete phosphorylation was 
responsible for oligomer dissociation. These interesting data still await confirmation in vivo. 
 
2.2. MAT II isoenzyme 
 MAT II has been especially studied in lymphocytes and in cancerous cells in which it is 
located in the cytosol [26]. Immunohistochemistry revealed that MAT II is located in distal 
tubules of kidney [27] and in liver stellate cells [28]. MAT II was purified to apparent 
homogeneity from human chronic lymphocytic leukemia cells; the purified enzyme showed a 
single band on native PAGE gels which was coincident with the MAT activity in gel slices [29]. 
Surprisingly, the preparation showed three bands in SDS-PAGE, with sizes of 53 ("2), 51 ("'2) 
and 38 (#) kDa. Peptide maps were identical for "2 and "'2, leading to the suggestion that they 
represent different post-translationally modified forms of the same subunit [29], the nature of this 
difference remains unknown to date. Subsequently, the MAT2A and MAT2B genes have been 
identified as encoding the "2 and # subunits.  The MAT2A gene consists of nine exons and 
eight introns covering !6 kbp [30], and is located on human chromosome 2p.1.1 [31]. Further 
information about the # subunit and its gene is provided in Section 2.2.1 (below).  The native 
molecular weight estimates obtained by both gel filtration chromatography and sedimentation 
velocity indicate an oligomer of approximately 185 kDa, a value compatible with several 
association arrangements ("22#2, "'22#2 or "2"'2#2). To date it has not been determined which 
of these defines the correct association state, but a tetramer is the accepted form. In addition, 
the presence of a 68 kDa precursor protein ($) for "2 and "'2 has been proposed, based on 
recognition of such a band by monoclonal antibodies raised against "2 subunits [32]. This 
protein, called $, is not detectable in continuously proliferating cells, and is lost upon induction of 
resting cells, wherein a parallel increase in "2 subunits occurs. The $ subunit showed MAT 
activity in cells where the "2, "'2 and # proteins were undetectable. Such a precursor protein 
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has not been observed in the non-mammalian organisms that express unusually large MAT " 
subunits [3], and its sequence has not been reported. 
 The kinetic properties of MAT II from human chronic lymphocytic leukemia cells have 
been characterized in detail, see Table 1 [29]. The enzyme has an optimal pH of 7-8.5, and is 
inhibited by AdoMet (with a Ki of 60 µM), PPPi, PPi, Pi, S-carbamyl-L-cysteine, polyamines and 
10% DMSO [29, 33-35]. The Km values have been reported as 31 and 3.3 µM for ATP and 
methionine, respectively. The kinetic mechanism, deduced from product and dead end inhibition 
patterns, is a steady-state ordered Bi-Ter with ATP adding first and AdoMet being the last 
product released [29]. 
 
2.2.1. The regulatory #-subunit 
 The presence of a non-catalytic #-subunit in MAT II was found by Kotb et al. [29]. This 
subunit was cytosolically localized by immunofluorescence visualization in transiently 
transfected Huh7 cells [36]. Peptide maps [29] and immunoreactivity [37] studies showed that 
the # protein is structurally unrelated to the "2 subunit. Expression of the #-subunit has been 
observed in all the extrahepatic tissues examined, and at very low levels in normal adult liver 
[36]. Purified MAT II from bovine brain [38], Ehrlich ascites tumor cells [38] and human mature 
erythrocytes [39], showed two types of bands on SDS-PAGE gels, one of them being 38 kDa. 
The sequence of a full length cDNA for the #-subunit of human MAT II isolated by LeGros et al. 
[40] showed that it encoded a protein of 334 amino acids (an ORF of 1002 bp), a calculated Mr 
of 37552 and a pI of 6.9. No sequence differences were found in the cDNA obtained from 
different cell types from several subjects; the ORF always started with the sequence Met-Val. 
Analysis of the deduced protein sequence revealed a 28% homology with bacterial enzymes 
that catalyze the reduction of TDP-linked sugars, several nucleoside-diphosphate sugar 
epimerases and other proteins involved in the synthesis of polysaccharides. Kyte-Doolittle 
hydrophobicity plots for # revealed two regions of prominent hydrophobicity with much higher 
scores than the three segments described for "2. Expression in E. coli of a His-tagged " 
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showed a protein of the expected molecular weight which was recognized by antibodies raised 
against N-terminal peptides of the #-subunit. These antibodies did not crossreact with "2 or any 
protein from either E. coli or yeast, confirming the absence of this type of subunit in these 
organisms. 
 The MAT2B gene consists of seven exons and six introns, spanning !6.8 kbp [41]. Exon 
1 contains 203 bp of the 5'-noncoding region in addition to 63 bp of the coding region, whereas 
exon 7 contains 117 bp of the coding sequence and 802 bp of the 3'-untranslated region. This 
gene was located in the long arm of the human chromosome 5, in an area that corresponds to 
the interphase between bands 5q34 and 5q35.1. A sequence of 1.1 kbp of the 5'-flanking region 
(along with several deletions) was tested for promoter activity in COS-1 and Jurkat T-cells, with 
little differences in behavior between the systems. Primer extension analysis allowed 
identification of the transcription start site 203 bp upstream the translation initiation site. The 
minimal promoter corresponds to the region +52/+93, a GC-rich sequence, the TATA box 
appears at -32/-8, and a Sp1 site was identified at +9/+15. Mutations of this Sp1 site and the 
TATA box reduced the activity 35-50% and 25%, respectively, whereas combination of both 
mutations rendered a 60% decrease. Supershift assays using anti-Sp1 and anti-Sp3 antibodies 
suggested Sp3 as one of the main factors that bind to the Sp1 site at +9/+15. Moreover, 
chromatin immunoprecipitation showed the involvement of Sp1 and Sp3 in complexes at the 
MAT2B promoter [41]. 
 The role of the #-subunit was not initially clear after its discovery. However, cloning of 
the "2 subunit and its expression in E. coli revealed important differences between the kinetic 
behavior of the homo-oligomer compared to the hetero-oligomer [42], leading to the suggestion 
of a regulatory role for the #-protein. This role was further supported by kinetic data obtained for 
MAT from peripheral blood mononuclear cells (PBMC) stimulated with superantigen (SEB), 
where the #-subunit expression was negligible and a 3-fold increase in the Km for methionine 
(55-67 µM) was observed in addition to a decrease in the sensitivity to AdoMet feedback 
inhibition [43]. Moreover, transient transfections of COS-1 cells with either "2, # or both subunits 
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showed changes in the kinetics for methionine saturation [44]. Expression of a His-tagged "2 
subunit showed two kinetic forms with Km values of 15 and 75 µM; expression of the #-subunit 
did not have an effect on Km, but increased the Vmax.  Moreover, coexpression of both 
subunits rendered an increase in specific activity along with a single Km of 20 µM for 
methionine.  Spontaneous association of the "2 and "'2 with # subunits was observed in both 
COS-1 [44] and Huh7 cells [36] and in cell free systems [44], which was reflected in changes in 
sensitivity to AdoMet inhibition. The purified recombinant #-subunit shows no MAT activity, but is 
able to modulate "2 kinetics, as well as those of the cMAT and MAT I/III "1 subunits [40, 44]. 
 
2.3. MAMMALIAN MAT REGULATION 
 Studies on MAT regulation in mammals have been carried out at different levels using 
animal and cell models, as well as purified proteins. The main achievements in the last decade 
probably correspond to the understanding of transcriptional regulation as described below. 
 
2.3.1 Transcriptional regulation 
 Sequences for MAT1A [45], MAT2A [30, 46, 47] and MAT2B promoters [41] have been 
obtained, allowing their analysis in different cell types.  
 Promoter analysis. The genomic clone obtained for rat MAT1A contained 1557 bp of the 
promoter, showing 88% identity to that of the mouse [45]. Its main characteristics are depicted in 
Figure 3. Briefly, the transcription initiation site is located 251 nt upstream of the ATG, a 
possible TATA box appears at -29/-23, and two canonical CAAT boxes are located at -379 and 
-1514. Several consensus sites for binding of specific trans-activating factors were also 
identified: 1) two putative AP-1 sites; 2) two PEA3 sites; 3) four glucocorticoid responsive 
elements; 4) two IL-6 binding sequences; 5) two NF-1 putative sites; and 6) one for each HNF-1, 
HNF-3 and HNF-4. Expression in hepatoma cells of promoter constructs linked to a luciferase 
reporter gene showed positive acting elements located at -1251/-958 and -193/-87, whereas 
regions -958/-727 and -375/-193 contain those elements in CHO cells. Footprinting analysis 
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using rat liver nuclear proteins showed eight DNase protected areas; the fragment -1251/-996 
contained binding elements for liver enriched factors at -1132/-1229, as judged from comparison 
with the results obtained using kidney and lung proteins.  Negative regulatory elements were 
also identified between -1154/-1134 in both H35 and CHO cells, an area where gel mobility shift 
assays revealed HNF-3 and HNF-1 binding.  Moreover, functional analysis of this promoter 
demonstrated its activity in hepatic and non-hepatic cells, suggesting that liver restricted 
expression is probably mediated by DNA methylation or genomic organization [45].  
Demonstration of MAT1A promoter hypermethylation in non-hepatic cells was obtained by 
Torres et al. [48], who also showed stronger histone acetylation in liver as expected for 
methylation silencing.  This same methylation pattern was observed in fetal hepatocytes, in 
livers from CCl4-induced cirrhosis and transformed cells [48].  Treatment of hepatoma cells with 
demethylating agents or histone deacetylase inhibitors increased MAT1A expression.[48]. 
 Analysis of the human MAT2A promoter sequence revealed several putative sites for 
transcription factor binding.  Among these factors, two sites for NF1 and AP-2, and one each for 
AP-1, c-Myb, NF%B and SpI were found [49].  Footprinting of the -163/+5 fragment showed three 
to five DNase protected areas, which varied depending on the type of cell extract used; 
phytohemaglutinin (PHA) stimulation did not induce the same pattern.  Four additional protected 
areas were identified using shorter promoter fragments, including three putative SpI sites in the 
-163/+5 fragment occupied as shown by supershift analysis [30, 46].  Positive elements 
responsive to TNF" have been also located in an area including NF%B and AP-1 consensus 
sites (-352/-314) [47].  Blocking NF%B with I%B superrepressor did not influence the capacity of 
TNF" to induce AP-1 binding to this promoter, but blockage of the AP-1 site with dominant 
negative cJun prevents induction of NF%B binding.  Electrophoretic Mobility Shift Assays 
(EMSA) using normal liver and HCC proteins identified c-Myb binding (-354/-328) in both cases, 
whereas differences were observed in the -60/-40 area.  One or two bands were shown in these 
cases for normal and malignant extracts, respectively, the differing band being ascribed to SpI 
binding [49]).  Both c-Myb and SpI are known to increase their expression levels in HCC. 
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 Effect of hormones and growth factors. Transcriptional regulation of MAT has been 
shown in several models.  Thus, MAT1A and MAT2A expression is modified in the presence of 
growth factors, such as HGF and TNF", as discussed in the MAT and Cancer and MAT and 
Ethanol sections, 12.3 and 12.4 respectively [47, 50].  Partial hepatectomy (PH) also induced a 
decrease in MAT1A mRNA levels, whereas those of MAT2A increase due to a rise in 
transcriptional activity and in mRNA stability [51].  In addition, hormones have been shown to 
modulate expression; adrenalectomy induces a reduction in MAT1A mRNA which correlates 
with decreases in protein and activity levels [52].  These effects were counteracted by 
administration of glucocorticoids, with synthetic forms being more effective [52].  Moreover, 
administration of triamcinolone to hepatoma cells increased MAT1A mRNA expression, with the 
protein levels following a similar trend.  Increases in MAT activity were also observed upon 
alloxan treatment, whereas the combined action of insulin and triamcinolone on H35 cells 
reduced this parameter [52].  On the other hand, insulin alone had negligible effects on MAT1A 
mRNA levels.  Confirmation of these effects was obtained using MAT1A promoter constructs 
and H35 cells treated with glucocorticoids; an increase in the decay rate of this mRNA was 
observed.  Development provides another model where alterations in expression can be related 
to hormonal changes.  In rat liver, MAT2A expression is reduced immediately before delivery, 
while a corresponding increase in MAT1A occurs [53]. 
 Effects of methionine and related metabolites.  The levels of methionine in the 
growth medium for hepatoma cells also influence expression.  Thus, deficiency of this amino 
acid in the medium induces MAT2A mRNA expression and increases its half-life, while AdoMet 
levels decrease [54].  AdoMet and methylthioadenosine (MTA) down-regulate MAT2A mRNA 
levels in the absence of transcription; the effects of MTA and methionine are carried out through 
their metabolites. The dependence of tumor cells on methionine for growth has been associated 
with defects in MTA phosphorylase expression which suppress this salvage pathway [55-58].  In 
addition, the influence of MAT1A expression on other pathways has been studied using a 
knockout (KO) mouse [59].  Disappearance of MAT1A expression correlates with up-regulation 
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of genes involved in cell communication, control of cell growth/maintenance, cell death and 
development, whereas down-regulation of genes for metabolic functions occurs. 
 Effect of oxygen levels.  Hypoxia can also modulate the glucocortocoid effect on 
MAT1A mRNA.  It also produces decreases in MAT1A transcriptional activity, but not in mRNA 
stability.  Concomitant GSH decreases and a reduction in MAT I/III protein levels, with no 
changes in isoenzyme ratio, were also observed [60, 61].  These effects are exerted through a 
heme-binding protein, and not through respiratory chain production of ATP, as judged from the 
response obtained using appropriate inhibitors.  H35 cells are resistant to MAT1A down-
regulation by hypoxia [62].  The role of oxygen tension is noteworthy among the factors that 
condition the functional heterogeneity of periportal and perivenous hepatocytes [63]. 
 Other effects. SEB induced an increase in "2/"'2 mRNA and protein levels, whereas #-
subunit expression was reduced and almost disappeared after 72 hours of treatment [43].  This 
down-regulation in #-subunit expression occurs with a 6-10-fold increase in AdoMet intracellular 
levels [43].  The opposite effect on AdoMet levels upon stimulation of DNA synthesis was 
observed for MAT2B expression in Huh7 cells[54]. 
 
2.3.2. Post-transcriptional regulation 
 Post-transcriptional regulation for MAT I/III was demonstrated in several models, with 
most studies confirming the important role of cysteines. 
 Regulation by glutathione levels. In vivo studies using rats showed that changes in 
GSH levels produced either by carbon tetrachloride treatment or by inhibition of glutathione 
synthesis by buthionine sulfoximine (BSO) were linked to decreases in MAT I/III activity [64, 65].  
A direct effect of glutathione on the enzyme was later demonstrated [8], showing inhibition by 
GSSG that could be modulated by GSH.  The mechanism for this effect excluded production of 
a mixed disulfide, and detection of monomers after GSSG inhibition suggested formation of an 
intrasubunit disulfide.  MAT III was shown to be more sensitive to GSH/GSSG action, and hence 
easier to oxidize.  In vitro modulation occurs in the 0-50 range of the GSH/GSSG ratio, as 
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expected for a strongly oxidizing environment, whereas physiological ratios between 10-300 are 
normal.  Inclusion of thioltransferases in the assay revealed that a thiol-disulfide exchange 
catalyzed by a protein disulfide isomerase-type enzyme could permit MAT regulation by 
disulfide formation in conditions of mild to severe oxidative stress [66].  The question remains 
whether C35-C61 is the only disulfide formed in the protein, or if other disulfides can partake in 
this type of regulation, and which thiol transferases are involved in such a regulatory mechanism 
in vivo. 
 Nitrosylation. Intraperitoneal injection of rats with bacterial lipopolysaccharide (LPS) 
induced serum accumulation of nitrites and nitrates, as well as expression of inducible nitric 
oxide synthase (iNOS) [18].  NO production induced by this treatment coincided with MAT I/III 
inhibition, but no reduction in protein levels or mRNA was observed.  In hypoxia, L-NAME (an 
inhibitor of iNOS) and N-acetylcysteine prevented MAT inactivation, but not changes in GSH 
levels. Treatment of hepatocytes with BSO had no effect on iNOS protein or mRNA, but induced 
a time-dependent increase in MAT III nitrosylation and inhibition [67].  L-NNA (NG-nitro-L-
arginine), an inhibitor of NOS with higher affinity for the constitutive enzyme, did not exert any 
effect on MAT activity or nitrosylation, nor on the GSH depletion caused by BSO.  However, 
recovery of GSH levels using glutathione monoethyl ester (EGSH) caused the loss of most of 
the NO groups incorporated on MAT III, and hence led to recovery of activity. Simultaneous 
administration of BSO and EGSH prevented the effect of BSO, thus suggesting that MAT 
inactivation induced by BSO takes place through S-nitrosylation of the protein. 
 Indirect data relate nitrosylation of MAT I/III with control of proliferation.  Intracellular 
levels of AdoMet are related to the differentiation state of the hepatocyte, with low levels of this 
metabolite in growing cells.  Knockout mice for iNOS show abnormal hepatic regeneration, and 
KO mice for MAT I/III have low AdoMet levels and induced expression of genes related to 
growth and differentiation [68].  The HGF and TGF" proliferative responses of isolated 
hepatocytes are inhibited by L-NAME, an effect which, for HGF, was overcome by concomitant 
administration of the NO donor SNAP.  This effect of L-NAME was dependent on L-methionine 
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concentration, and since inhibition of NO production activates MAT I/III, AdoMet levels also 
increased [69]. 
 Using purified MAT I/III and NO donors such as SIN-1, S-nitrosylated glutathione 
(GSNO) and S-nitroso-N-acetylpenicillamine (which has no structural relationship to 
glutathione), a direct inhibition of the enzyme was obtained that did not affect the 
oligomerization state of the protein [18, 21].  This inhibition was reversed by either GSH or #-
mercaptoethanol.  GSNO reduced the Vmax for both isoenzymes, and increased the S0.5 of MAT 
III for both methionine and ATP [21].  In the search for NO the reactive residues, cysteine 
mutants of MAT were used, which revealed that C121S was resistant to SIN-1 action, whereas 
the C69S, C105S and C150S mutants were more sensitive than the wild type enzyme. This 
regulation by nitrosylation should be specific for MAT I/III, since the thiol of C121 has no 
equivalent in MAT II which has glycine at that position. 
 The mechanism proposed for protein S-nitrosylation involves an acid-base catalyzed 
nitrosothiol exchange reaction, where the target cysteine is localized next to acidic and basic 
residues [70], requirements that were met by MAT I/III.  Site-directed mutagenesis allowed 
identification of the residues involved, D355, R357 and R363, and confirmed their role [71].  
Incubation of recombinant MAT III with peroxynitrite also inactivates MAT without nitrosylation, 
an effect that was prevented in the C121S mutant, whereas D355S, R357S, R363S and 
R357S/R363S substitutions had no effect.  Residue 121 is a glycine in MAT II, however it was 
possible to create an equivalent nitrosylation site by the mutation G120C, as demonstrated 
using recombinant MAT II and GSNO [72].  Equivalent acidic and basic residues are preserved 
in MAT II (D354, R356, R362), thus allowing modification of position 120 in the G120C mutant.  
No effect of nitrosylation on the basal tripolyphosphatase activity of MAT I/III was detected, but 
its stimulation by AdoMet was reduced in the presence of NO donors [73]. These authors 
suggested the presence of two MAT III isoforms, one of low tripolyphosphatase activity which is 
insensitive to NO, and another of high activity which is inhibitable by this agent.  Interconversion 
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between the two conformations would be a slow process that results in a lag phase detected in 
kinetic studies. 
 Hydroxylation. Treatment of a stable CHO clone overexpressing MAT I/III (ST-C) with 
hydrogen peroxide showed enhanced cell death as compared to the wild type CHO cells [74].  
Analysis of these cells showed that H2O2 further depletes the NAD and ATP levels that were 
already 50% reduced in the ST-C clone.  This effect could be prevented using an inhibitor of 
poly (ADP-ribose) polymerase, 3-aminobenzamide (ABA), but not with the antioxidant N,N'-
diphenylphenylenediamine (DPPD).  In vitro, purified MAT I/III was inactivated by hydrogen 
peroxide in a dose dependent fashion, the effect being exerted at the Vmax level [75].  This 
inactivation was reversed in the presence of GSH, and had no effect on the oligomeric state of 
the isoenzymes.  However, the GSH concentration needed for this reversal of MAT I (25 mM) is 
far beyond the physiological levels of this metabolite (!5 mM), and hence oxidation was 
suggested as the cause for the low tetramer activity observed in cirrhosis.  Site-directed 
mutagenesis allowed identification of C121 as the site of oxidation by hydrogen peroxide.  
However, inhibitory effects were also observed related to other cysteine residues (69, 105, 312 
and 377).  Hydrogen peroxide treatment of ST-C cells had no effect on the amount of MAT 
protein and reduced the activity in this clone, but not in wild type CHO cells or CHO-T121, a clone 
overexpressing the C121S MAT mutant.  This effect was mediated by hydroxyl radicals as 
demonstrated by the use of desferrioxamine, an inhibitor of the Fenton reaction.  Again this type 
of modification should be specific for the MAT I/III isoenzymes since C121 is not present in other 
MATs.  Free radical mediated MAT inactivation was suggested as an adaptive response to a 
nitrosative or oxidative stress, aimed at preserving ATP cellular levels [61].  On the other hand, 
a long lasting interruption of MAT activity would stop many important cellular functions. 
 Other regulatory models.  MAT1A changes upon partial hepatectomy (PH) are 
regulated at a post-transcriptional level through factors that do not need de novo protein 
synthesis.  These alterations cause decreases in AdoMet levels, increases in those of AdoHcy, 
and hence reductions in the AdoMet/AdoHcy ratio.  In addition, DNA methylation is decreased, 
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whereas GSH levels rise; this last effect could help maintain MAT I/III activity [51].  This type of 
regulation is also observed as an early effect upon hepatocyte incubation under low oxygen 
concentrations [61].  The initial MAT inactivation with concomitant AdoMet and GSH reduction 
correlates with MAT I/III protein decreases after 24 hours.  Inactivation under these conditions is 
mediated by nitric oxide (NO), as judged from increases in inducible nitric oxide synthase 
(iNOS) transcripts and the blockage of MAT inhibition in the presence of L-NAME, an inhibitor of 
iNOS. The partial protection observed with N-acetylcysteine also suggests a role for GSH in this 
regulation.  Ceramide stimulation of hepatocytes or H35 cells induces a reduction in MAT I/III 
expression [76].  Such induction is also observed upon IL-6 addition, either alone or in 
combination with ceramides.  This decrease in protein correlates with the reduction in activity 
[76]. 
 Regulation of MAT II isoenzyme.  Changes in the relative amounts of the different 
MAT II subunits have been observed upon stimulation with T-cell mitogens [32].  PBMC cells 
incubated with phytohemagglutinin (PHA) sequentially increase their IL-2 production, followed 
by their MAT activity and lastly DNA synthesis [32].  Analysis of the amount of MAT II subunits 
by Western blot revealed an increase in "2, and more dramatically in #'2, whereas #-subunit 
levels remained constant.  Kinetic analysis by Hanes-Woolf plots indicated the presence of two 
enzymatic forms catalyzing AdoMet synthesis in activated cells.  Increases in activity preceding 
protein synthesis could be due to post-translational modifications, leading to alterations in the 
relative amounts of "2/"'2 and, hence in their oligomerization with #-subunits.  These changes 
in the amount of MAT II subunits during activation were not observed in other cell lines, such as 
Jurkat or freshly isolated PBMC cells from acute lymphocytic leukemia ALL-2 patients.  In those 
cases activation induced IL-2 production, but no increase in MAT activity or change in the 
relative amount of MAT II subunits was observed [77].  Moreover, the use of SEB as stimulator 
also caused activation of PBMC cells and a 2-fold increase in MAT II activity, but the changes in 
the relative amounts of the subunits differed from those observed with PHA treatment [77].  
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 3. MAT IN PLANTS. 
 Plant cells need AdoMet to carry out a variety of specific AdoMet dependent processes, 
such as ethylene formation [78] and lignin polymerization [79], as well as the functions essential 
for their viability that are common to other organisms [80].  To accomplish these needs the 
presence of up to seven MAT genes has been described in some plants [81-91].  Some of these 
genes lack introns [87] and contain short leader sequences (9-13 nucleotides) [81, 82].  Most 
studies have been carried out using Arabidopsis thaliana as a model.  Comparison of the SAM1 
and SAM2 genes of this plant revealed a high divergence among the sequences flanking the 
ORFs [81].  However, the promoters possess three regions of conservation that are candidates 
for the presence of cis-acting elements responsible for organ-specific expression [82].  The 
ORFs encode proteins of approximately 394 residues and are highly homologous to each other 
(up to 96% identical at the amino acid level) and to the E. coli and yeast enzymes (50-60%) [3].  
However, exceptions to this conservation were observed in wheat embryos and dwarf pea 
epicotyls, where subunits exhibited 84-87 kDa molecular weight on SDS-PAGE gels [92-94].  
The native enzyme chromatographed normally as dimers [92, 94], except for the Caranthus 
roseus isoenzymes which were recovered as monomers after gel filtration chromatography [87].  
In addition, associated tripolyphosphatase activity has been observed in MATs purified from 
wheat embryos [92], and, as occurs with other MATs, the importance of cysteine residues in 
three Arabidopsis thaliana isoenzymes has been shown using NEM and DTNB [95].   
 Expression varies among different parts of the plant, for example SAM1 of Arabidopsis 
has higher mRNA levels in stem and root as compared to leaves, and this pattern is directly 
correlated with MAT activity levels [81].  Such data suggest that regulation takes place mainly at 
the transcriptional level.  Moreover, expression is primarily located in vascular tissues, 
sclerenchyma and root cortex.  The strong cellular preference in the expression of the SAM1 
gene seems to be, at least partly, correlated with the extent of lignification the tissues are 
undergoing.  In addition, several models showed up-regulation of MAT gene expression, protein 
levels and activity at different stages during development : i) during germination [92, 96]; ii) in 
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early stages of development of leaf and root [85]; iii) in young stems, sepals and corollas [97]; 
iv) during initiation of fruit development [86]; v) in steps preceding anthesis [98]; vi) during 
adventitious root development [99]; and vii) in the pre-storage phase of endosperm development 
during early desiccation [100].  On the other hand, down-regulation occurs in other steps, such 
as after anthesis [86, 101].  Hormonal, nutritional and stress regulation of plant MATs is linked 
to the above mentioned changes.  Thus, gibberellic acid induces expression of two isoenzymes 
in dwarf pea epicotyls, an effect blocked by cycloheximide [94], and reduces expression in 
ovaries after anthesis [86, 101].  Auxins induce MAT during fruit development [86].  Salt stress 
and drought induce differential expression of MAT isoenzymes in tomato seedlings, an effect 
that can be due to a combination of ion toxicity and osmotic stress, the latter inducing synthesis 
of abscisic acid (ABA) [84, 85, 102, 103].  Such differential expression is also obtained with 
mannitol and ABA treatment, as well as upon wounding.  The reason for such induction may be 
the need for larger AdoMet amounts for either cell wall synthesis or modification.  Moreover, 
these stimuli also increase ethylene biosynthesis, a common process for plant response to 
environmental stress.  MAT genes are also among the genes whose expression increases in 
relation to pathogen defense upon exposure to fungal elicitor [104].  Several methylation 
reactions are known to be associated with pathogen defense, most notably the formation of 
diverse classes of phenylpropanoid derivatives.  Ethylene biosynthesis is also stimulated in 
elicitor-treated leaves [104]. 
 Regulation by nitrosylation has been studied in Arabidopsis thaliana isoenzymes [95].  
Only recombinant SAM1 was inhibited by GSNO, the modified residue being cysteine 114.  This 
residue is located close to the putative substrate binding site, at the loop of access to the active 
site according to a structural model, and flanked by amino acids that promote nitrosylation 
(TKCPEE).  Crosstalk between ethylene and nitric oxide (NO) signaling has been proposed at 
the level of MAT regulation through nitrosylation of C114 of the SAM1 isoenzyme, whereas the 
other isoenzymes are not affected significantly [95, 105].  Production of NO regulates key plant 
defense networks, and thionitrosyl (SNO) formation and turnover are required for multiple 
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modes of disease resistance.  Finally, overexpression of Arabidopsis SAM1 in tobacco plants 
has phenotypic effects such as the appearance of dark green sectors in leaves [106].  The dark 
sectors have reduced MAT activity and silencing of the transgene.  On the other hand, 
transgenic plants with suppressed MAT activity produce the methanethiol associated with 
cabbage odor, as do methionine treated plants [106]. 
 
 4. MAT IN YEAST 
 The understanding of MAT has greatly benefited from the use of yeast as a model 
organism. The observation that some yeast strains accumulate large intracellular concentrations 
of AdoMet in UV-dense vacuoles [107-109], which also have high levels of polyphosphate as 
counter ion, has led to the use of yeast fermentation as a route to commercial production of 
AdoMet.  The pioneering mechanistic work of Mudd in the 1960s utilized bakers yeast 
preparations [110-114]; it is unknown whether these contained mixtures of the isozymes that 
were only discovered a decade later by Chiang and Cantoni [115].  These authors obtained the 
first preparation of pure, catalytically active MATs, and found two isozymes in the genetically 
heterogeneous bakers yeast.  SDS-PAGE gels showed that each isozyme had two distinct 
types of subunits with apparent molecular weights of 55 and 60 kDa, forming hetero-dimers with 
a native molecular weight of 110 kDa.  Both MATs had tripolyphosphatase activity and 
displayed requirements for divalent and monovalent cations.  The steady state kinetic data 
showed downward curvature in double-reciprocal plots for both ATP and methionine; this was 
interpreted as negative cooperativity, although the same observations could result from the 
simultaneous action of two enzymes with different kinetic parameters.  The kinetic parameters 
are listed in Table 1 along with those of other purified MATs. 
 Using the yeast Saccharomyces cerevisiae, Surdin-Kerjan and coworkers identified 
mutations in two genes that caused reductions in MAT activity; these genes are denoted SAM1 
and SAM2 (originally called ETH10 and ETH2 because the mutations were selected by their 
conference of resistance to ethionine) [116, 117].  The SAM1 and SAM2 encoded MAT subunits 
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are 92% identical in polypeptide sequence.  The genes are differently regulated, with methionine 
inducing SAM2 expression while repressing that of SAM1 [118].  The same authors constructed 
a strain that combined mutations in SAM1 and SAM2; this strain had no MAT activity and 
required AdoMet for growth, providing the first evidence that this metabolite is essential for any 
organism.  The construction of deletion mutants that are totally defective in AdoMet synthesis 
was possible due to the ability of S. cerevisiae to import AdoMet from the media via the specific 
transport protein encoded by the SAM3 gene [119].  More recently several obligate intracellular 
parasitic organisms have been found to have AdoMet transport systems which compensate for 
the absence of an encoded functional MAT (see MAT and Parasites, Section 8). 
 
 5. MAT IN BACTERIA 
 Most bacteria have a single copy of a structural gene for MAT, which is highly 
homologous to the eukaryotic form [3].  The protein appears as a homotetramer in which early 
studies demonstrated the importance of cysteine residues [120].  The modification of two 
cysteines per subunit of the Escherichia coli MAT (cMAT) led to inactivation and dissociation to 
inactive dimers, followed by aggregation.  Identification of the modified cysteines revealed 
cysteines 90 and 240 of cMAT as the labeled residues.  There are few biochemical data 
regarding the regulation of the activity of bacterial MATs, with the exception of the potent 
product inhibition of cMAT by AdoMet [121].  The transcriptional regulation of MAT in both Gram 
positive and Gram negative bacteria has been extensively studied. In both cases, the 
expression of the structural gene for MAT, generally denoted metK, is regulated in conjunction 
with the genes of the enzymes of methionine biosynthesis [122-125].  
  In Gram positive bacteria, such as Bacillus subtilis, the "S-box" riboswitch metabolite-
sensing RNA binds AdoMet and regulates the expression of at least 26 genes, including the 
metK gene [126-129].  The dissociation constant for AdoMet binding to this riboswitch RNA is 
10 nM; the complex acts as a transcriptional terminator [129].  In contrast, Gram-negative 
bacteria regulate metK expression through use of the metJ repressor protein in a complex with 
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AdoMet as corepressor [130].  Expression of the metK gene of E. coli is also repressed by Lrp 
(leucine regulatory protein) [131]. 
 
 6. ARCHAEAL MATs 
 The existence of an archaeal MAT activity was first demonstrated in Sulfolobus 
solfataricus extracts [132].  The subsequent purification of MAT from Methanococcus jannaschii 
enabled identification of the gene within the completed genome sequence [133].  The sequence 
of M. jannaschii MAT is widely diverged from that in eucarya or most bacteria, retaining ca. 18% 
sequence identity [133].  Close homologues of the M. jannaschii MAT are found in both 
Crenarchaeota and Euryarchaeota.  Thus, a dramatic phylogenetic differentiation in MATs 
occurred early in evolution.  It is unclear whether the difference in archaeal vs. 
bacterial/eucaryotic sequences reflects convergent or divergent evolution.  The biochemical 
properties of archaeal MATs are generally similar to those from bacteria and eucarya providing 
no clue as to a functional meaning of the sequence divergence [132-134].  Thus, the M. 
jannaschii MAT is a dimer, has tripolyphosphatase activity, and requires both divalent and 
monovalent metal ions for activity [133, 134].  Recombinant, highly thermostable, M. jannaschii 
MAT is readily produced in E. coli and its ability to use a variety of nucleotides in addition to ATP 
may make it a useful synthetic tool [134].  How MAT activity is regulated in archaea remains 
unknown.   
 
 7. BACTERIA WITH ARCHAEAL-TYPE MATs. 
 The finding that the sequence of MATs in the archaea is substantially different from that 
in eubacteria or eucarya enabled computational identification of organisms with both types of 
MAT in their genomes [133].  The archaeal type of MAT has not been found in any eucarya, nor 
has the eucaryotic/bacterial class of MAT been discerned in any archaea (unpublished results).  
However several bacteria have been identified as possessing both the expected type of MAT 
and the archaeal type.  These bacteria are widely scattered throughout phlyogengy.  These 
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organisms include: Aquifex aeolicus, a deeply branching bacterium which encodes both types of 
MAT in its small 3 Mb genome; the gram positive human pathogen Streptococcus pyogenes 
(but not other Streptococci); several Chlorobaicaes such as Chloribium tepidum and Pelodictyon 
lutelum; the Alphaproteobacterium Bradyrhizobium japonicum;  the Betaproteobacteria 
Ralsotnia eutropham, Burkholderia vietnamiensis and Pelobacter carbinolicus; and several 
Delatproteobacteria (Delta proteobacterium MLMS-1, Pelobacter propionicus, Syntrophus 
aciditrophicus and several members of the Geobacter group).  Proteomic studies of 
S. pyogenes [135] and G. sulfurreductans [136] show that both types of MAT proteins are 
indeed expressed, implying functionality.  The metabolic reason for the presence of two types of 
MATs in these organisms remains to be elucidated. 
 
 8. MAT IN PARASITES 
 Many parasitic organisms have MATs with atypical properties, and even in a few cases 
have no MAT and are thus AdoMet auxotrophs (recently reviewed in [137]).  The parasitic 
fungus Pneumocystis carnii is unable to synthesize AdoMet, but has two AdoMet transporters 
with Km values of 4.5 and 333 µM [138, 139].  Trypanosomes of the Trypanosoma brucei group 
are amongst organisms that both have MAT and are able to transport AdoMet from the media 
via a specific transport system [140].  These organisms lack the capacity for de novo purine 
synthesis.  It is relevant that the AdoMet level is reported to be 70 nM in human sera [141], 
whereas the Km for the transporter is in the 4–10 millimolar range [142].  Thus, transport will be 
inefficient in vivo.  Trypanosomal MATs are unusual in that they are not regulated by AdoMet, 
with Ki values in the millimolar range, in contrast to the micromolar values for AdoMet inhibition 
of MAT from most organisms [143].  Amongst the Leishmania, Leishmania infantum, a 
trypanosomatid protozoan parasite, has two MAT genes in a tandem array.  Two AG 
dinucleotide trans-splicing sites are located in its 5!-UTR, and the +420/+905 region of the 3´-
UTR contains cis-regulatory elements [144].  These genes are expressed as a single transcript 
[145]; the resultant protein forms a dimer.  Surprisingly selenomethionine and cycloleucine did 
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not inhibit their MAT activity, and AdoMet had a remarkably high Ki of 1.5 mM. Leishmania 
dovanii, also has two MAT genes [146].  The properties of the purified enzyme have been 
studied with particular attention to the importance of cysteine residues in folding and catalysis 
[137, 146].  These authors also showed that truncations at F382, D375 and F368 of MAT 
sequence resulted in loss of MAT activity and reduction of tripolyphosphatase activity [147].  An 
internal deletion, E376&F382, preserved a high tripolyphosphatase activity that is not stimulated 
by AdoMet [147]. 
 The MAT from the protozoan parasite that causes malaria, Plasmodium falciparum, has 
been cloned and a molecular model was constructed based on the cMAT crystal structure [148].  
The authors proposed this enzyme as a target for the development of new anti-malarial drugs.  
The enzyme had a high Ki for cycloleucine as compared to a human hepatic MAT (17 mM vs. 10 
mM); little additional characterization was reported. 
 The Amoeba proteus xD strain harbours symbiotic X-bacteria; these bacteria become 
obligatory endosymbionts in a process that is accompanied by a change in the MAT isozyme 
expressed by the amoeba [149, 150].  The lack of expression of the ameoba!s primary MAT is 
due to lack of transcription rather than mutations to the gene itself. Apparently the bacterium 
becomes essential to the survival of the amoeba by modification of the expression of the host 
MAT gene.  The mechanism of AdoMet exchange between the two organisms has not been 
reported. 
 Obligate intracellular bacteria have been found in which the metK gene encoding MAT is 
present but not functional [151, 152].  Among these are Chlamydia trachomatis [153], the # 
proteobacterium Rickettsia prowazekii, and other members of the spotted fever group of 
Rickettsia.  The metK gene in these Rickettsia is regarded as a marker for the process of the 
degradation of genes that have become unnecessary as a result of changes either in the habitat 
of the organism or the gain of redundancy accompanying horizontal gene transfer [154].  In 
contrast, a functional MAT is present in Rickettsia of the typhus group [155].  R. prowazeiii have 
a characterized transporter than can import AdoMet from the host [155], and which is functional 
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when expressed in E. coli [156].  Finally, Nanoarchaeum equitans is the only known archaeal 
parasite; it also lacks a gene for MAT in its small 0.5 Mb genome [157], but the nature of its 
acquisition of AdoMet remains unknown. 
 
 9. STRUCTURE AND CATALYTIC MECHANISM 
 9.1. Structures of MAT 
 Crystal structures have been reported for the rat MAT I (cf. pdb code 1QM4 (2.7 Å 
resolution) [23]), the human MAT IIa (pdb code 2PO2 (1.03 Å) [158]) and cMAT (cf. pdb codes 
1XRA, 1XRB and 1XRC, 1FUG) [159, 160]. As might be expected from their sequence 
similarity, the overall topology is the same for each protein (RMSD for alpha carbons = 1.3 Å 
between rat and human; 0.78 Å between E. coli and human).  The structure of MAT is unique 
among all protein structures determined to date.  The topology is described in the SCOP 
database (http://scop.berkeley.edu/data/scop.b.htm) as belonging to the Alpha + Beta protein 
class, and there are no other members of the MAT superfamily.  Three repeats of beta-alpha-
beta(2)-alpha-beta secondary structure are found; notably there is no significant sequence 
conservation within the structural repeats (illustrated for the human MAT IIa in Figure 4a).  
These repeats constitute the three domains of the subunit which are formed by non-consecutive 
stretches of the sequence. The dimer of the enzyme forms in an inverted arrangement so that 
the two active sites are located in a deep cavity between the subunits (Figure 4b). The tilt 
between the dimers of MAT I is distinct from that of cMAT; the human MAT II structure has not 
yet been analyzed in detail.  A tetramer forms from the association of two dimers at right angles 
at their central tips (Figure 4b).  The hydrophobic interface between monomers in the tight 
dimers is much more extensive than is the polar interface between pairs of dimers, consistent 
with interconversion of the dimeric and tetrameric forms of the mammalian MAT I and III and the 
stability of the dimer. 
 The majority of the reported MAT structures share a disordered loop segment (residues 
117–128 in rat MAT I, 102–107 for cMAT) that forms a dynamic lid over the active site. The only 
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structures in which this lid is ordered are of the human MAT II complex with AdoMet (pdb code 
2PO2 [158]), the cMAT both in a ligand free form (1FUG [160]) and in structures with the active 
site filled with methionine and the ATP analogue AMPPNP (or the products of the reaction in the 
crystal, AdoMet and PPNP (1RG9, 1P7L [161]).  Other structures in which only some of the 
ligand binding sites are occupied have the a lid segment disordered, suggesting that motion of 
the lid is involved in allowing access of substrate and products to the active site, an 
interpretation supported by kinetic and spectroscopic studies of cMAT [162, 163]. 
 Structures for several MAT complexes have been published.  These include: i) cMAT in 
complexes with ADP, BrADP, PPi and the ternary complex with AMPPNP and methionine [159, 
161, 164]; ii) rat MAT I in binary complexes with L-cisAMB or aminoethylphosphonate (AEP), 
and ternary complexes including ATP plus methionine, ATP plus AEP, and ADP plus L-cisAMB 
[23, 165]; and iii) the AdoMet complex of human MAT II [158].  The ADP binding site observed 
in binary complexes with cMAT (1MXB, 1MXC) is essentially the same as that found in MAT I 
ternary complexes (1O93 and 1O9T).  Moreover, both enzymes hydrolyze ATP to ADP and Pi, 
and hence in some of the complexes where ATP was added ADP was observed. The 
methionine binding site determined for MAT I in complexes with the methionine analogues L-
cisAMB and AEP is also similar, with stacking against Phe-251 (Figure 5a). In addition, the 
three phosphates appear also in analogous positions for rat and E. coli enzymes [23, 159], the 
P' being oriented against a putative P-loop previously identified by photoaffinity labeling [166].  
However, differences arise between ligand locations in ternary complexes.  Thus, in the rat MAT 
I•ATP•methionine complex (1O9T, 2.70 Å) additional density compatible with AdoMet appears in 
a different orientation than ATP.  The cMAT•AMPPNP•methionine complex (1P7L, 2.50 Å) 
shows interchanged positions for the methionine and adenine moieties which is observed also 
in active sites containing AdoMet + PPNP (which were formed by reaction of AMPPNP and 
methionine in the crystal (Figure 5b; pdb codes 1PL7 and 1RG9)). Figure 5c shows the ligand 
positions when the E. coli and rat MAT I protein structures are superimposed (see the active site 
histidine (residue 14 or 30, respectively) at lower right).  This AdoMet location in the E. coli 
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complex superimposes on that for AdoMet in the MAT II-AdoMet structure (2PO2) Figure 5b).  
In the structures of the MATII•AdoMet and cMAT•AdoMet•PPNP complexes the adenine ring 
stacks against the phenylalanine in the position occupied by L-cisAMB and AEP in the MAT I 
complex structures.  The location of two phosphoryl groups (which might be expected to be 
relatively well located in the X-ray data due to the grouping of heavy atoms) is preserved 
throughout.  At present the origin of the differences between AdoMet locations in MAT I and 
E. coli or MAT II structures are unclear, but could either reflect the various other ligands bound 
(see the legend to Figure 5), or represent the positions for AdoMet as a product and as an 
inhibitor.  Available mutagenesis data for the two proteins do not discern which is the functional 
configuration.  Resolution of this difference will be of major importance in understanding the 
enzyme mechanism. 
 Among the questions that await a structural solutions are the structure of the regulatory # 
subunit and its sites of interaction within MAT II isozyme. The high sequence similarity of the " 
subunit to nucleotide sugar reductases of known structure, such as dTDP-rhamnose reductase 
(26 % identity, 49 % similarity over 235 residues) suggests that the protein fold can be 
recognized by homology.  The structure of dTDP-rhamnose reductase (pdb code 1vl0 with 
bound NADH, 2.05 Å resolution) shows a NAD-binding Rossman fold.  No available data 
indicate the sites at which the MAT II # and " subunits interact, or if NAD(H) is involved.  It will 
also be intriguing to see the structure of an archaeal type MAT since the sequence similarity to 
the eukaryal/bacterial MATs is very low, and differences in circular dichroism spectra suggest 
that the proteins have different #-helical content, perhaps implying different topologies.  
Nevertheless the few residues which are conserved in a sequence alignment are primarily 
located in the active site of the bacterial/eucaryotic MATs [134].  There are no reported 
structures of proteins with significant sequence homology to the archaeal MAT. 
 
9.2. Kinetics and mechanism 
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 Studies of the kinetic mechanism of MAT catalysis date to the pioneering work of Mudd 
in the 1960's (reviewed in [167].  Many of the seminal reports are unfortunately complex 
because before the studies of Chiang and Cantoni [115] it was not realized that in many 
organisms there are co-purifying isoforms.  Even in systems with pure isozymes kinetic studies 
have been challenging, due several unusual behaviours: 1) low concentrations of AdoMet 
activate its own synthesis by yeast MATs [112, 168], 2) the rat MAT III shows complex 
hysteretic behavior with a temporal lag phase before the steady state rate is attained [73] and 
3) severe non-competitive inhibition by the product AdoMet, particularly with cMAT [121].  
Nevertheless the overall picture that has emerged for MAT from various organisms is 
remarkably consistent.  A common overall physical basis for the kinetic mechanism appears 
applicable, however among MATs there are physiologically significant variations in the detailed 
rate constants (and,equally importantly from an overall perspective, the ratios of the rate 
constants and thus relative KM values).  
 The two yeast MATs show negative cooperativity for both ATP and methionine [115], the 
non-hepatic rat MAT II isozyme displays negative cooperativity for methionine [169], while the 
rat MAT III shows positive cooperativity with a Hill coefficient of 1.8 [169].  Hence in many cases 
the concentration dependences of substrate saturation are referred to S0.5 values rather than KM 
values. 
 All studies point to a sequential kinetic mechanism, as illustrated in Figure 6.  There is 
1) formation of a E•ATP•Met complex, 2) reaction to form an E•AdoMet•PPPi complex as an 
obligatory tightly enzyme-bound intermediate and 3) the subsequent hydrolysis of PPPi before 
regeneration of the free enzyme [112, 121, 170]; reviewed in [167, 171].  Variations in rate 
constants among MATs from different organisms, combined with a diversity of experimental 
conditions, can account for the observed differences in steady state kinetic mechanisms.  These 
differences are seen in the apparent order of substrate binding for example, with ATP being first 
(most eucaryotic MATs and the archaeal M. jannaschii MAT) vs. random addition (e.g. E. coli, 
although in this case in the preferred order of binding ATP also binds first [170]).  The order of 
 9/14/2012             Page 30 of 80 
product release is also variable with the most obvious path being taken by the E. coli enzyme, 
where the products are liberated in order of diminishing affinity, i.e. Pi before PPi, before 
AdoMet. 
 In terms of interconversion of enzyme-bound substrates and products, extensive early 
work by Mudd and others demonstrated that the only detectable reaction intermediate was PPPi, 
[111]; no covalent enzyme-intermediates have been identified, either in AdoMet formation or in 
PPPi hydrolysis. PPPi is hydrolyzed in a predominantly oriented fashion; > 95% of the Pi 
originates from the '-phosphoryl group of ATP, and PPi from the ", # groups [110].  This 
demonstrates that PPPi is tightly bound during turnover so that the rate of escape from the 
enzyme, or even of reorientation of this symmetric compound within the active site, is slow 
compared to hydrolysis.  The position of the '-phosphate is preserved in the crystal structures to 
date, showing the active site structure at different steps of the reaction in which movement of 
the "- and #-phosphates, as well as on the ribose moiety is observed [161, 164, 165].  The site 
of bond cleavage as O#' -P' was shown by the incorporation of 
18O from H2O
18
 solely into Pi 
[110]. 
 The AdoMet activation of its own synthesis in the reaction catalyzed by the yeast MATs 
[111, 168] and MAT III [169]; deserves note: this phenomenon appears to reflect the escape of 
AdoMet from the E•AdoMet•PPPi complex before PPPi hydrolysis, which results in E•PPPi 
hydrolysis becoming rate limiting in turnover.  The rate of exogenous AdoMet binding to E•PPPi 
becomes comparable to the rate of E•PPPi  hydrolysis and the hydrolysis rate accelerates after 
AdoMet re-binding to form E•AdoMet•PPPi complex.  In general MATs catalyze the hydrolysis of 
added PPPi, and the rate of this reaction is increased by added AdoMet.  Most MATs show the 
anticipated product inhibition of the overall reaction by AdoMet.  
 
 9.3. Chemistry of Catalysis 
 A significant contribution to understanding the chemical mechanism of catalysis was the 
determination of the stereochemical course of the yeast MAT reaction using chiral [5'-2H]-ATP 
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[172].  The chiral [5'-2H]-AdoMet was formed with inversion of stereochemical conversion at 
carbon-5'.  This result demonstrated that an odd number of displacements takes place at 
carbon-5', which is most simply attributed to a direct displacement of the PPPi chain from ATP 
by the sulfur of methionine.  Subsequent kinetic isotope effect measurements with the E. coli 
enzyme showed a 13% reduction in catalytic rate when 14C replaced 12C at the C5' of ATP which 
demonstrates that the bonding change at C5' is involved in the rate limiting step of the reaction 
[173].  The magnitude of the 14C effect was near the theoretical maximum, and there was no 
detectable secondary isotope kinetic effect from 5'-3H; the observed isotope effects from 35S and 
[methyl-3H]methionine showed the involvement of methionine in the displacement step.  The 
combined data demonstrate that AdoMet is formed in a classical SN2 displacement mechanism 
with simultaneous attack of the sulfur of methionine on the C5' of ATP and displacement of the 
PPPi chain [173]. 
 The unique catalytic task of MAT is thus to facilitate the attack of methionyl sulfur on 
ATP to form AdoMet, a reaction in which charge separation occurs to yield the sulfonium cation 
and an additional negative charge on the polyphosphate chain.  It is remarkable that when 
bound to the enzyme the equilibrium for the formation of AdoMet and PPPi lies far towards the 
products, i.e. at the active site the PPPi hydrolysis step is not needed for product accumulation 
[111, 121, 170].  Rather PPPi hydrolysis facilitates product release by the cleavage of the tightly 
bound PPPi intermediate to the more weakly bound PPi and Pi. 
 The mechanism of hydrolysis of the PPPi intermediate appears to be similar to that of 
the myriad of metal ion dependent ATPases and other phosphatases [174].  However the 
chemical means by which water is activated to react with the PPPi and thus split the 
polyphosphate chain into PPi and Pi is unknown.  The hydrolysis reaction requires Mg
2+ and in 
many MATs it is stimulated by K+, although the effect of K+ is typically not as large as is seen for 
AdoMet formation.  It is not clear from the available crystal structures whether a metal activated 
water (or hydroxide ion) is involved in this step of the reaction, or whether a protein group 
activates water.  The active site arginine (R244 in cMAT, R265 in MAT I) is critically important 
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for orienting the PPPi for hydrolysis [175].  It is an intriguing possibility that one of the residues in 
the conserved Lys-Arg sequence may be unprotonated and acts as the catalytic base; an 
unprotonated arginine has been recently proposed to be the catalytic base in other hydrolytic 
reactions [176].  However, the R244L mutant of cMAT had less than a 10-fold decrease in 
tripolyphosphatase activity [175]; the K245M mutant had >100-fold decrease in PPPase activity, 
but CD spectra showed that it was incorrectly folded precluding definitive interpretation [177]. 
 Kinetic and spectroscopic studies of cMAT have revealed that protein conformational 
changes are coordinated with catalysis [163, 170, 178].  Pre-steady state and solution viscosity 
dependence kinetic studies of cMAT show that a conformational change occurs in conjunction 
with the formation of AdoMet and PPPi, and a second change occurs after PPPi hydrolysis [163, 
170, 178].  These changes probably involve movement of the protein loop that covers the active 
site in some crystal structures but is disordered in others [23, 159-161, 165].  This loop is the 
least conserved region of the protein sequence among eucayal/bacterial MATs and varies in 
length from 6 to 19 residues [3].  The closure of the active site loop would prevent release of the 
PPPi intermediate before hydrolysis.  The movement of protein loops to sequester reaction 
intermediates while allowing access of substrates and release of products is a common feature 
in enzyme catalyzed reactions [179-181].  Blockage of substrate access to the active site of 
MAT I/III by nitrosylation has been suggested as a physiological regulatory mechanism [18].  
Nitric oxide modification of C121 in this flexible loop may stabilize its closed conformation thus 
impeding the entrance of the substrates for catalysis.  
 
 9.4. Metal Ion Activation 
 MAT from all sources requires Mg2+ or another divalent metal ion for activity, and where 
it has been examined, a monovalent cation such as K+ has been found to enhance the reaction 
rate on the order of 100-fold (studies that have specifically address the cation activation include 
those in [29, 113, 115, 121, 182].  The monovalent cation effect has not always been noted 
because other ions such as Na+ and NH4
+ can substitute for K+, and these cations are commonly 
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present as counter ions of ATP or buffer components.  Crystal structures show that the active 
site of MAT is highly polar, with many charged residues.  This is consistent with the course of 
the reaction in which additional charges accumulate as first AdoMet and PPPi form, and then 
upon creation of PPi and Pi, presumably with release of one proton from water.  Thus, a role for 
cations in stabilizing the new negative charges is easily rationalized. 
 Binding studies in conjunction with EPR and NMR spectroscopic investigations of cMAT 
have shown the presence of two divalent cations and one monovalent cation at the active site 
[183-186].  EPR studies of the Mn2+ activated enzyme showed that two Mn2+ ions bind very 
closely together, which crystallographic studies confirmed, showing two divalent cations 5.2 Å 
apart, with both binding to the phosphate groups; one ion coordinates all three ", # and ' 
groups. while the second coordinates the "- and '-phosphoryl groups.  The coordination of two 
metal ions to the leaving "-phosphoryl group could play a substantial catalytic role by stabilizing 
the negative charge formed upon C-O bond rupture.  A monovalent cation binds at distances of 
3.8 and 8.1 Å from the two divalent ions.  The sole protein ligand to this ion is the carboxylate of 
E42, and mutation of this residue to glutamine abolished monovalent cation activation [187].  
Neither crystallographic, solution spectroscopic nor mutagenesis studies have indicated that the 
monovalent cation directly binds to the substrates, and this ion appears to play an indirect role 
in organizing the active site structure [187].  The crystal structure of the E. coli enzyme revealed 
an additional monovalent cation bound between two subunits in the tight dimer; this ion appears 
to play a role in dimer stability and is conserved in the MAT I structures.  The crystal structures 
of the rat MAT I enzyme have shown as many as three Mg2+ at the active site [23, 165].  One of 
these cations interacts with the carboxylate of the substrate methionine or an analogue such as 
L-cisAMB or AEP; such an interaction is not observed in any of the cMAT structures.  The two 
additional PO4 are each within 4 Å of the phosphates of ATP (1O9T) in the MAT I structures; the 
significance of these phosphate ions are unclear. 
 
 9.5. Mutagenesis Probes of the Mechanism 
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 The crystal structures of MAT have directed mutagenesis studies of active site residues.  
In these it has been advantageous to examine possible selective effects of the mutation on both 
AdoMet synthesis and on the hydrolysis of added PPPi.  The high evolutionary conservation of 
the active site residues implies little tolerance for variation, therefore it is not surprising that most 
mutations impair the enzyme function.  For the E. coli MAT, all mutations of polar active site 
residues have had larger effects on the AdoMet formation step than on the PPPi hydrolysis 
reaction [163, 175, 177, 187, 188], which is consistent with the singular active site architecture 
known for the former activity and the variety of known ways that enzymes catalyze hydrolysis of 
polyphosphate chains. The only mutations which affected the tetrameric state of the cMAT were 
C89A and C90S from which separate and non-interconverting dimers and tetramers were 
isolated, with a ca. 10–fold reduction in kcat for the tetramer and an additional 20-30 fold 
reduction in the dimer [189]. 
 The most informative mutagenesis result for the E. coli enzyme may be that mutation of 
the active site arginine-244 to leucine (see Figure 5b) resulted in a reduction of 1000-fold in kcat 
for AdoMet formation, and a remarkable ability of the PPPi intermediate to reorient within the 
active site before hydrolysis, showing the importance of the guanidinium in stabilizing the 
intermediate conformation [175].  In contrast to the R244L and R244H mutants of cMAT which 
remained tetrameric and retained wild type secondary structure as indicated by CD spectra, the 
R265H mutant of MAT I eluted in gel filtration chromatography with a calculated Mr of 41000, 
corresponding to a monomer [190].  This mutant was reported to have no AdoMet synthesis 
capacity (2% of wild type), but preserved the tripolyphosphatase activity, its Vmax for hydrolysis 
being similar to that shown by the wild type MAT (128 vs. 156 nmol/min/mg).  A R265S mutant 
was also found to be a monomer, but in this case along with a 99% reduction in AdoMet 
synthesis a 5-fold decrease in tripolyphosphatase activity was also detected. These results 
together suggest the involvement of the positive charge at 265 in hydrolysis.  No association of 
the mutant monomers was observed under assay conditions, as judged by gel filtration 
chromatography (41.6 kDa).  However, coexpression with the wild type protein produced hetero-
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oligomers (90 kDa on gel filtration chromatography) with tripolyphosphatase activity.  This 
arginine 244 (or 265 in rat) residue is involved in a salt bridge with E58 of the opposite subunit, 
one of the few polar interactions formed at <3.5 Å between monomers in the dimer, and this 
interaction is preserved in MAT I crystal structure [23, 164].   
 Active site mutants (D180G, K182G, F251D and F251G) prepared on rat MAT I and 
overexpressed in E. coli showed no AdoMet synthesis capacity, but preserved PPPi hydrolysis 
activity.  It is noteworthy that the PPPase activity of F251 mutants is double than that shown by 
the wild type protein.  A possible explanation for this fact may be that the reduction in size of the 
lateral chains in those mutants facilitates accessibility for PPPi.  Moreover, all these mutants 
were able to bind ATP with Kd values similar to that of the wild type (10.54 ± 0.85 mM) [23].  
Thus, mutations at the methionine binding residue (F251) only prevent AdoMet synthesis.  
 
 9.6. Solvent effects on MAT activity- practical consequences 
 A phenomenon that has aided discrimination among the mammalian MAT forms is the 
(10-fold DMSO activation of the rat MAT III isozyme [191, 192], the molecular basis for which 
has not been resolved.  The ability of molar concentrations of mercaptoethanol, acetonitrile and 
other compounds to alleviate the potent non-competitive inhibition of the E. coli MAT by AdoMet 
has facilitated synthetic applications [193].  Significant changes in the far-UV CD spectra of 
cMAT are associated with the addition of these co-solvents, suggesting substantial alterations in 
protein folding. No analogous structural data have been reported for the mammalian MATs. 
 
 10. MAT FOLDING 
 Studies on MAT folding have been carried out mainly in vitro using rat MAT I/III with urea 
and thermal denaturation.  The high conservation in sequence and structure found between " 
subunits of eucarya and bacteria make these results extrapolable to most of the known MATs, 
probably with the exception of the large subunits observed in some plants.  In vivo data are 
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restricted to the identification of cMAT as one of the proteins folded by the E. coli GroEL/GroES 
complex [194].   
 10.1. MAT III folding under equilibrium conditions Folding of MAT III, the rat 
liver MAT dimer, was studied using urea as the perturbing agent.  The enzyme used for these 
studies was either the DTT-refolded protein from E. coli inclusion bodies at concentrations 
below 0.2 mg/ml [195] or the rat liver purified dimer [196].  In both cases the equilibrium 
experiments showed the reversibility of the process that occurs through a three-state 
mechanism (Figure 7).  Data were obtained by activity measurements, fluorescence 
spectroscopy, CD, sedimentation velocity and gel filtration chromatography.  These techniques 
allowed following of the process at different levels, i.e. the active site, the tertiary structure, the 
secondary structure and the subunit association level.  The loss of activity preceded the 
changes detected by other techniques, and occurs earlier for AdoMet synthesis (D50% = 0.3M) 
[195] than for tripolyphosphate hydrolysis (D50% =1M) [196]. ANS binding showed a similar trend, 
exhibiting a single transition at these low urea concentrations (D50% of 1 M) [196].  Both 
fluorescence spectroscopy and far-UV CD showed two transitions with a plateau at 1-2 M urea, 
an interval at which monomers where detected by both gel filtration chromatography and 
sedimentation velocity [195, 196].  Maximal fluorescence emission for MAT III appears at 334 
nm, with intensity decreasing by denaturation as the maximum is displaced to 355 nm [195].  
Thus, in the three-state mechanism for MAT III unfolding the activity is lost before dissociation to 
a monomeric intermediate (I). 
 The structure of intermediate (I) allows limited proteolysis that produces a 3 kDa 
fragment, which as deduced from mass spectroscopy data, corresponds to a N-terminal cut at 
lysine 33 [196].  Other characteristics of intermediate (I) include: a 2.5-fold decrease in 
tryptophan fluorescence intensity; preservation of a 70% of the secondary structure of native 
MAT III; and, a 75% lower ANS binding as compared to that of the native dimer [195, 196].  All 
together these data indicate that this intermediate (I) shows features of a molten-globule.  
Accumulation of the intermediate was estimated to be maximal between 2-2.5M urea as 
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deduced from tryptophan fluorescence and CD data.  Unfolding data obtained using the active 
site monomeric mutant R265H [190, 196] also show the presence of an intermediate, thus 
confirming its monomeric structure [196].  However, this intermediate seems less compact than 
monomeric R265H as judged from its larger hydrodynamic volume.  Data obtained with this 
mutant however should be considered with care, since analogous mutants obtained for cMAT 
behave as tetramers [175].   
 The apparent stoichiometry of ANS binding was determined to be 1 mol ANS per MAT III 
subunit, suggesting its binding to a specific site [196].  This location appears to correspond to 
the start of the loop at entrance to the active site, where there is a similar environment to that 
found in the crystal structure of another ANS-protein complex [197].  Monomers in the crystal 
structure of MAT I [23] have a large flat hydrophobic contact surface, thus solvent exposure of 
this interface would lead to a rearrangement in the subunit for hydrophobic burial.  Such a 
rearrangement is suggested by the different ANS binding properties shown by the dimer and 
monomeric intermediate (I), as well as by the high value of the m1 constant calculated for the 
dissociation process in urea denaturation.  Unfolding of the intermediate would further require 
minimal changes to render the unfolded protein. 
 Analysis of all these data using models for different unfolding mechanisms showed the 
best fit for a three-state process involving a monomeric intermediate [195, 196].  The global m 
coefficient for urea dependence was 7.25 kcal/mol/M, whereas the value obtained for the global 
free energy change was calculated to be 15.7 kcal/mol.  This low dimer stability toward urea 
denaturation is mainly derived from the low !G1(H2O) value that represents 50% of the global 
stabilization energy for MAT III (subunit association).  The importance of the monomeric 
intermediate (I) is highlighted by refolding experiments that include a two step process in which 
the 2 M urea intermediate is favoured before the total elimination of denaturant.  Such a two-
step process allows not only a 100% recovery of the activity, but also provides a better yield 
when using inclusion bodies as the enzyme source [198].   
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 MAT III is one of the many proteins made up of two identical subunits.  The proliferation 
of such an arrangement may involve some advantage for the cell.  Recently, it has been 
proposed that the oligomerization process itself might tune the enzymatic function [199].  These 
authors indicate that the formation of intersubunit contacts influences the biological activity by 
allowing very subtle conformational changes in the active site in such a way that oligomerization 
can indeed activate the monomeric subunits.  Moreover, the fact that a 50% of the free energy 
for unfolding represents dissociation processes is consistent with the idea that contacts at the 
surface hidden between the monomeric subunits plays a fundamental role in the stabilization of 
oligomeric proteins.  For dimers of a given size, those proteins that have a folding intermediate 
displayed less empty volumes [199].  The role of dimerization in proteins of class B (N2) 2I ) 
2U), such as MAT, is mainly structural according to Mei et al [199].  The dimerization process 
for this type of proteins might find a rationale in the protection and stabilization of those molten 
globule states that alone are not able to complete their self-assembly process. 
 
 10.2. Kinetic intermediates 
 Two kinetic intermediates have been identified during MAT I unfolding by fluorescence 
spectroscopy (Figure 7).  The first one (Ik
2) occurs during the MAT III-intermediate I transition 
[196].  The data fit to a single exponential, corresponding to a monomolecular process, thus 
indicating that the folding pathway includes at least one kinetic intermediate (Figure 7).  More 
evidence for the presence of such intermediate was obtained by ANS binding in the presence of 
tripolyphosphate, where a transient binding of the dye was observed at 1-2.3 M denaturant.  
These results suggest that even though Ik
2 is not well populated it must bind a large amount of 
dye to allow detection.  No direct information about the association state of Ik
2 was obtained, and 
hence its monomeric state was inferred from other results [196].  Moreover, Sánchez del Pino 
et al. speculated that the shape of Ik
2 could be that of a folded or a well structured monomer, and 
hence have a large solvent-exposed hydrophobic interface which should be energetically 
unfavoured, leading to a very fast association.  In addition, such a conformation would also 
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explain the high unspecific binding of ANS to Ik
2.  This kinetic intermediate is also shared by the 
monomeric R265H mutant, prior to attaining its final folding, thus suggesting its monomeric 
character.   
 Another kinetic intermediate was identified in the tetramer-dimer association step using 
DTT-refolded MAT [17].  DTT-refolded tetramers and dimers appear in a concentration 
dependent equilibrium and are not distinguishable by either tryptophan fluorescence or CD 
[198].  However, MAT I dissociation could be followed by ANS fluorescence [17], showing an 
exponential decay to ANS-dimer fluorescence in a process that yields the best fit as a single 
exponential.  Calculations of the half-life of MAT I render a value of 14.69 ± 0.5 s [17], in 
contrast to the 858 s previously obtained for the cytosolically overexpressed oligomer [200], but 
the studies differed in the temperature used.  Again, the association state of this new kinetic 
intermediate (Ik
1) cannot be determined directly due to its short lifetime.  However, the fact that 
its ANS fluorescence intensity is the same as that shown by the tetramer suggests that it might 
be a dimer that has just separated from the tetramer, before undergoing the changes needed to 
achieve the MAT III conformation.  These changes cause reduction of its affinity for methionine 
[7, 8], as well as acquisition of DMSO activating capacity, and a higher hydrophobic character 
[191].  Moreover, in order to be detected by this technique these structural changes should 
occur close to the ANS-binding site that, as postulated by Sánchez del Pino et al., is located 
close to the active site loop [196].  The free energy change for MAT I dissociation was 
calculated as -6.99 kcal/mol, which along with the data derived from MAT III unfolding, give a 
global free energy change for MAT I unfolding of 24.41 kcal/mol [17].  Further analysis looking 
for the presence of additional intermediates in this dissociation process will rely on the use of 
stopped-flow techniques. 
 
 10.3 Thermal unfolding 
 Two-dimensional infrared spectroscopy (IR), activity and tryptophan fluorescence 
spectroscopy were used to follow thermal unfolding of MAT [201].  The high protein 
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concentrations needed for IR precluded the study of dimers, since the equilibrium between DTT-
refolded MAT forms was clearly displaced towards the tetramer.  On the other hand, the low 
protein concentrations needed for activity and fluorescence measurements allowed analysis of 
the dimer behaviour.  IR spectra in H2O and D2O are dominated by two bands at 1652 and 1636 
cm-1 attributed to #-helix and "-sheet, respectively.  A band at 1624 and 1626 cm-1 in D2O and 
water, respectively, agrees with MAT I existence as an oligomer.  The secondary structure 
composition was calculated to be 44% #-helix, 37% "-sheet, 18% "-turns and a very low 
percentage of unordered structure, in agreement with structural and CD data.  Thermal 
unfolding was irreversible by all the techniques used in this study, showing a Tm of 47-51ºC 
[201].  Activity and tryptophan fluorescence measurements revealed one transition for dimer 
unfolding that occurs in the same temperature range as the IR changes for the tetramer.  Such a 
result indicates that MAT I stability is highly dependent on that of the dimer.  Moreover, the IR 
data show no change in the "-sheet band (1635 cm-1) with temperature, whereas the 
corresponding #-helix band is split in two, with a reduction in the helical percentage [201].   
 Analysis of synchronous and asynchronous 2D IR maps gives information about which 
structures are changing and the order of events taking place at each temperature, respectively.  
As deduced from this study, native MAT I starts its unfolding at 37ºC, the dominant crosspeak 
being centered at 1622 cm-1, which corresponds to changes in protein contacts and beginning of 
aggregation.  The initial changes, according to asynchronous maps, correspond to peaks of "-
helix, unordered structure and #-turns, structural elements located at the external surface of the 
subunits [23].  Moreover, changes in the 1624 cm-1 band indicate alterations in the 
oligomerization state that could be assigned either to T-D-M or T-M processes [201].  The 
unfolding continues, showing aggregation at the expense of the remaining secondary structures, 
in coincidence with changes in activity and tryptophan fluorescence that could be ascribed either 
to dimer dissociation and monomer aggregation or just aggregation of the unfolded dimer.  No 
further changes are detectable after complete activity loss.  Thus, MAT I thermal unfolding starts 
with changes in the structures of the hydrophilic surfaces, followed by loss of tertiary structure to 
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render a dimer, possibly enzymatically active in a narrow range of temperature, and leading, 
finally, to unfolding and aggregation.  A special characteristic shown by MAT is the ability of 
some structures to interconvert during the process, a new aspect of denaturation events [201].   
 
 10.4. Association of MAT III to render MAT I: role of the disulfide C35-C61 
 As mentioned before, rat liver MAT appears in a protein concentration dependent 
equilibrium upon overexpression in E. coli [17, 198, 200], a fact that has not been observed in 
the MAT I and III forms purified from liver.  On the other hand, GSH/GSSG-refolding renders a 
mixture of tetramers and dimers that do not interconvert, and that can be isolated as stable 
entities [198].  These results raised the question as to what feature modulates the association 
properties of MAT.  The obvious difference among both refolding procedures is their different 
redox potential which might be crucial for a protein that contains 10 cysteine residues per 
subunit.  Thus, analysis of the number of free sulfhydryl groups for each species was performed 
by chemical modification, and mass spectrometry showed 10 free sulfhydryls/subunit in DTT-
refolded MAT, whereas only 8 were detected for GSH/GSSG-refolded MAT I and III [17].  The 
previous identification of the disulfide linking C35-C61 in rat liver purified MAT [22] prompted the 
analysis of a possible role for such a disulfide in stability.  Such a study was performed using 
both refolding systems and cysteine mutants (C35S, C57S, C61S and C69S) located in the 
central domain of the subunit and at disulfide bonding distance according to the MAT I crystal 
structure [23].  Analysis of their behavior by analytical phenyl Sepharose chromatography, 
showed persistence of the dimer-tetramer equilibrium for GSH/GSSG-refolded C35S and C61S 
[17], thus suggesting a role for the residues involved in the disulfide bond in the MAT III to MAT I 
association process.  Mass spectrometry analysis of the oxidized residues in GSH/GSSG-
refolded MAT confirmed the existence of the C35-C61 disulfide, and hence that this modification 
stabilizes both tetramers and dimers.   
 The question remained as which is the step of the folding process where this disulfide is 
established.  Two structures could be suitable for this purpose, MAT III and Ik
1 (Figure 7).  MAT 
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III could undergo oxidation, in which case association would be precluded, or evolve to render Ik
1 
which then evolves to the tetramer.  This kinetic intermediate could also be the subject of 
oxidation, a process that would then preclude the conformational changes that lead to MAT III, 
and hence produce the oxidized tetramer.  All these events would take place at the central 
domain that establishes the contact between dimers in the tetramer structure.  The tetrameric 
arrangement is maintained by only five polar interactions between dimers in rat liver MAT, with a 
small area in direct contact with the solvent.  The dissociation constant for these proteins was 
calculated to be 105 M, a value comparable to those described for proteins showing 
association/dissociation behaviour [200, 202], but much lower than that for cMAT (1010 M) [120].  
Such a large difference in the constants is in agreement with all the data obtained to date with 
cMAT and its structure which shows a much larger contact surface between dimers.  Thus, the 
few interactions that maintain MAT I can be easily modified/avoided by just a small 
rearrangement in the central domain, or by a higher flexibility of its secondary structure.  The 
presence of the C35-C61 disulfide would stabilize this domain and facilitate the correct pattern 
of interactions between dimers.   
 
 10.5 Complementary folding data obtained in MAT proteins of different origins 
 The critical role of C69 in dimer association was shown by site directed mutagenesis 
studies of the rat liver protein, where C69S appeared mostly as low activity dimers upon 
overexpression in E. coli cytosol [19].  However, DTT-refolding from inclusion bodies showed an 
increase in the specific activity of that mutant, reaching a 64% of that of the wild type, as well as 
production of tetramers [17].  These data indicate a blockage of the folding pathway for C69S in 
bacterial cytosol that can be overcome in vitro.  Cysteines at residues 61 and 69 are specifically 
found in liver MATs, and hence can be related to the special behaviour exhibited by these MAT 
forms.  Both residues, as well as C57, are located in #-sheet B2, the position of C69 being close 
enough as to form a disulfide bond with C57 upon a slight torsion of the main protein chain [23].  
However, it could be possible that under certain circumstances, such as during folding, this 
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second disulfide is formed either alone or in concordance with the C35-C61 disulfide, a 
possibility that would be precluded for C69S.  Thus, blockage of the normal folding pathway 
could led to disulfide arrangements that would certainly render alterations in #-sheet B2, the 
contact area between dimers.  Such changes would obviously alter the oligomerization pattern.   
 Folding studies carried out with Leishmania donovani MAT showed proper folding only 
under reducing conditions, with cysteines 22, 44 and 305 being crucial for the global process 
[146].  Conformational transitions were observed via fluorescence quenching during refolding 
from E. coli inclusion bodies in the presence of DTT.  Such transitions generated fast and large 
events that took place during the first two hours of reaction, and were found to be essential for 
activity recovery.   
 A mixture of tetramers and dimers was also described for the cMAT mutants C89A and 
C89S [189]; C89 is located at the border between dimers with no involvement in strong 
interactions [164].  However, C89 is a conserved cysteine residue for MAT proteins of different 
organisms, thus suggesting an important role for such amino acid in dimer production.  If this is 
the case, the structure of the dimer interface might be changed substantially by cysteine to 
alanine replacement leading to more labile liver-type arrangement.   
 
 11. MAT INHIBITORS. 
 The multitude of metabolic roles of AdoMet, and its involvement in modulation of cell 
growth, have resulted in an enduring search for MAT inhibitors with in vivo and in vitro utility.   A 
selection of the most effective inhibitors produced to date, some of which have been used for 
structural studies, are shown in Figure 8, and their inhibitory properties are included in Table 2.   
The most widely used inhibitor has been the amino acid analog cycloleucine, since it is long 
established and commercially available [206]; with its Ki in the millimolar range and possible 
additional effects in vivo it is clearly not an optimal inhibitor.   
 The inhibitor design process has included analogues of both substrates ATP and 
methionine, both which have been tested in cancerous cell lines.  Much of this work has been 
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carried out in the laboratories of Hampton and Sufrin (cf. [203, 204]); the two laboratories had 
significantly different approaches and have provided much information that we cannot analyze in 
depth in this review.  Their results will be invaluable to the future development of potent, 
bioavailable, isozyme selective inhibitors.  Hampton and co-workers strove for maximal 
inhibitory potency by linking the methionine methyl to the reactive 5' position of the nucleotide 
substrate, forming bi-substrate analogs; isozyme selectivity was achieved by further 
modification of these inhibitors.  These compounds had sub-micromolar affinity for the rat 
isozymes, however the compounds are only available by complex synthetic routes, and this 
work has not been extended to yield bioavailable compounds.    
 Sufrin has focused on methionine analogues, which are permeable to many types of 
cells, and her L-cis-AMB (L-2-amino-4-methyl-cis-but-3-enoic acid) has proven to be a useful 
tool for in vivo inhibition of MAT, notably in trypanosomes [205].  A related analogue, L-2-amino-
4-methythio-cis-but-3-enoic acid (L-cisAMTB), is a competitive inhibitor against the amino acid 
with Ki of 21 and 5.7 µM against MAT I and II, respectively . It is also a substrate with Km values 
of 555 and 33 µM.  This inhibitor is 2-10-fold more potent against hepatoma MAT than against 
liver isoenzymes [204].  L-cisAMTB has more structural fidelity to methionine than the oxygen 
analog L-cisAMB.  The highly planar conformation of the hydrophobic enol ether chain of L-
cisAMB was anticipated to be exhibited by L-cisAMTB.  However, X-ray crystallography 
demonstrated a slight torsion and a consequent deviation in planarity on the thioenol ether side 
chain [204], which may be reflected in the difference in affinity.   
 Among the methionine analogs, cyclic 5-membered ring amino acids bind with optimal 
affinity to all of the isozymes tested [206].  Recent studies with 4,5-epoxide and 4,5-epithio 
methionine analogs have provide inhibitors with affinity as high as 7 µM for recombinant rat liver 
MAT, although none were found to irreversibly inhibit the enzyme by covalent modification [207].  
The 2'-hydroxyl of ATP and the dianionic form of the '-phosphate of ATP may play a role in the 
reversible binding to these enzymes.  The low Vmax exhibited by 2'-deoxy-ATP in MAT II 
suggested a possible implication of the 2'-OH in catalytic events [208, 209].  All of the 2-, 3- and 
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4-mono-C-methyl derivatives of methionine assayed are low affinity selective inhibitors of MAT II 
and tumor MAT, and the three exhibiting the highest inhibition are competitive inhibitors against 
methionine [210].   
 Diimidotriphosphate (O3P-NH-PO2-NH-PO3), which is
 a nonhydrolyzable analogue of the 
tripolyphosphate intermediate, is a slow binding inhibitor with nanomolar affinity for the E. coli 
and M. jannaschii enzymes; studies with eucaryotic MATs have not been reported [134, 211].  
The slow binding and high affinity were associated with a protein conformational change after 
the initial binding, events that were attributed to ionization of one of the –NH- groups when the 
compound is bound to two metal ions at the active site [161].  The commercially available 
imididiphosphate (O3P-NH-PO3) is also a slow binding inhibitor of cMAT with a Ki of 0.8 µM 
[211].   
 
 12. ROLE OF MAT IN DISEASES 
 Data from many studies link changes in MAT activity to the development of different 
types of disease.  Such changes lead to the corresponding alterations in AdoMet levels, and 
hence in the many reactions in which this compound is involved.  Thus, in many cases a direct 
relationship between the development of the disease and MAT is difficult to establish.   
 12.1. Cognitive and neurodegenerative diseases 
 Alterations in transmethylation mechanisms in neurodegenerative diseases such as 
Parkinson, Alzheimer and subacute combined degeneration of the spinal cord have been 
demonstrated [212-215].  Similar defects have been suggested to occur in complex psychiatric 
disorders, such as schizophrenia and dementia [216].  In mice, monkeys and pigs an 
association has been found between a defect in methionine synthesis and/or MAT activity and 
the development of myelopathies, ataxia, peripheral neuropathy and subacute combined 
degeneration of the spinal cord [217-219].  Moreover, Charlton and Way showed in 1978 that 
AdoMet injection into the lateral ventricle of rats and mice produced tremors, rigidity and 
abnormal posture [220].  Blood AdoMet and AdoHcy levels have been shown to decrease in 
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Parkinson!s patients, combining to yield a lower AdoMet/AdoHcy ratio, whereas erythrocyte 
MAT activity was found to be increased [215].  However, no association between AdoMet and/or 
AdoHcy levels, or MAT activity, and the age or the duration of Parkinson!s disease has been 
described.   
 Parkinson's disease is a disorder marked by degeneration of nigrostriatal dopaminergic 
neurons, and consequential depletion of both dopamine in the basal ganglia, and melanin in the 
susbtantia nigra pars compacta.  L-dopa administration is the major treatment for this disease, 
leading to an increase in hepatic and brain levels of AdoMet and AdoHcy at short-term [221].   
However, AdoMet depletion occurs upon long-term therapy with this compound, which results in 
losses of efficacy [222-225].  Short-term treatments also produce increases in brain (48%) and 
liver (34%) MAT activities that parallel increments in the corresponding protein levels detected 
by Western blot [221].  Moreover, the levels of MAT and catechol O-methyltransferase (COMT) 
mRNA are increased by L-dopa, which also induces transcription factors such as NF-1 and 
cJun/AP-1 that are known to control MAT and COMT promoter activities.  Clinical improvements 
(reduced tremor and rigidity) in these patients have been also reported after treatment with 
methionine [226].  In the presence of AdoMet, COMT methylates L-dopa to 3-O-methyldopa, 
and this treatment results in increased MAT activity in brain [227].  The frequency of 
administration and the duration of the treatment are related to the induction observed.  A sudden 
rise in dopamine may be responsible for hyperkinesias that can occur following L-dopa 
administration, since motor activity has been associated with such increases [228].  On the 
other hand, the dimethylated product of dopamine is known to be hypokinetic [229].  Thus, it is 
proposed that patients from whom L-dopa control of the disease is long-term may be resistant to 
the induction of MAT activity, whereas those in which the L-dopa treatment is ineffective may 
initially have enhanced MAT activity at the onset of therapy.  There is also substantial evidence 
which indicates the neurotoxicity of L-dopa, for which the proposed mechanism is the generation 
of hydrogen peroxide and oxyradicals resulting from oxidation of dopamine in the nigral neurons 
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and its nerve terminals.  Thus, it is possible that L-dopa accelerates the rate of dopamine 
neuronal degeneration as a result of this direct neurotoxicity [230].   
 Schizophrenia has been also extensively studied, due to its high incidence (1% of the 
population worldwide).  The rate of whole body methionine metabolism in these patients is 
reduced to one third that of controls [231].  Significant increases in blood Hcy [216], low MAT 
activity in erythrocytes [232], regionally selective decreases in MAT!s Km for methionine [233] 
and low serine hydroxymethyltransferase [233] have also been reported.  Some of these 
alterations were also found in individuals with dementia (Gomes-Trolin 1996).  Exacerbation of 
schizophrenic symptoms was observed in response to large oral doses of methionine [234], 
whereas AdoMet is a reported antidepressant [235].  Profound defects in membrane 
phospholipids of lymphocytes have been also detected [236], phospholipid methylation being 
stimulated by dopamine, epinephrine and norepinephrine, as well as serotonin in neuroblastoma 
SK-N-MC cells [237].   
 
 12.2. Human mutations in MAT1A gene: hypermethioninemia and demyelination 
 Mutations have been characterized by single-strand conformation polymorphism (SSCP) 
and DNA sequencing for patients showing isolated persistent hypermethioninemia (Table 3).  
However, MAT deficiency is not the only alteration related to the presence of high methionine 
levels in plasma.  Such an increase could also take place transiently during the neonatal period, 
disappearing when the dietary intake of proteins is reduced [238, 239], or as a consequence of 
CBS deficiency, or due to deficieny in fumaryl acetoacetate hydrolase (tyrosinemia type I) or 
liver disease.  Therefore, newborn children are routinely screened for hypermethioninemia [240], 
a small percentage of those who show isolated persistent hypermethioninemia have 
deficiencies in hepatic MAT or glycine methyltransferase (GNMT) [241].  Definitive positive 
diagnosis however requires demonstration of reduced MAT activity in liver biopsies, a procedure 
that has been precluded in many cases due to the absence of pathological symptoms.  Some 
patients present unusual breath odor, due to large increases in dimethylsulfide levels [242, 243], 
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while others have neural demyelination [15, 214].  In cases where liver biopsies were available, 
a reduction in MAT!s Km for methionine was also observed [244, 245].  The plasma levels of 
methionine in this type of patients may be as high as 1.3 mM (35 µM for normal levels), but the 
presence of 50-60% MAT activity is enough for maintenance of a normal level of the amino acid 
[15, 240].  On the other hand, MAT activity in the erythrocytes, lymphocytes or fibroblasts of the 
patients is normal [14, 243].   
 The first patient with MAT deficiency was an infant described by Gaull in 1974, [246], 
and subsequently since more than 60 individuals with mutations in the MAT1A gene have been 
identified (Table 3).  Most of the mutations described were found to follow a recessive 
autosomal inheritance trait.  However, gene tracking in families showing the G to A transition at 
nucleotide 791, leading to R264H, revealed a Mendelian dominant inheritance [245, 247, 248].  
Some of the mutations lead to stop codons in the ORF (Table 3), and hence to truncated forms 
of the protein.  Subunits of 91 [249], 184 [15, 250], 349 [15, 240], 350 [15] and 386 residues 
[251] will result from these changes.  In addition, a mutation at the wild type stop codon has also 
been described, rendering a longer protein [252].  Only truncated forms of 349 and 350 amino 
acids are present in patients developing demyelination, a result that lead to the hypothesis that 
the size of these anomalous subunits allows partial folding to an intermediate state that is able 
to associate with the wild type subunits.  Thus, these truncated proteins may sequester MAT2" 
subunits in inactive heterodimers, whereas shorter proteins (i.e. 184 residues) cannot.   
Heterodimerization was also suggested for the 386 residue truncated protein, however, no 
validation was provided [251].  The presence of truncated subunits will lead to a lack of 
methylated products, among them phosphatidylcholine and creatine which are important for the 
myelin in neural sheath and neural structure [253].  These data, along with experiments carried 
out in rats that were given cycloleucine [254], suggested that AdoMet administration may 
overcome, at least in part, these problems.  However, only one of the patients showing 
demyelination was treated with AdoMet and responded to this therapy [214].  Kim et al. [251] 
also indicate that the physiological effects may be due to lack of AdoMet rather than to 
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hypermethioninemia, and suggested that elevation of methionine levels may promote a greater 
flux through the remaining MAT, thus alleviating AdoMet deprivation.   
 Polymorphisms such as that of T to C at nucleotide 426 have been also detected in 
MAT1A gene [15].  Other silent mutations in exons III (C225T rendering A75A) [248], VIII (C to T 
in intron 8 and C882T rendering A292A)[255], and IX (T1131C, leading to Y377Y)[248, 255] 
have also been observed.  Another interesting mutation occurs in the last nucleotide of exon III.  
This change alters the splice-donor site, and hence, could either render normal (G98S) or 
anomalous splicing.  Analysis of both possibilities was carried out, showing normal activity for 
the G98S mutant, whereas minigenes indicated the presence of abnormally large products 
[249].   
 Some of the mutant MATs have been expressed in COS-1 cells and/or E. coli in order to 
study their activity and association state to understand the behaviors shown by the patients.  
Thus, truncated proteins of 349 and 350 residues, as well as, the mutants R199C, R356Q and 
G378S were prepared and shown to follow the same trend in both systems.  Only R356Q 
(53%), R199C (10%) and G378S (<0.1%) displayed MAT activity [15].  A more detailed analysis 
was carried out at the R264 position, the results suggesting the necessity of a positive charge at 
that position to attain maximal activity [248].  Moreover, some of the mutants at this position 
were able to homo- or hetero-dimerize [248, 249].  The hetero-oligomerization shown by R264H 
and wild type subunits explained its dominant effect on MAT activity.  Analogous mutants 
prepared on other MATs show differences in the oligomerization pattern [175, 190].  Thus, MAT 
I/III R265H mutant behaves as a monomer with tripolyphosphatase activity, whereas c-MAT 
R244H remained a tetramer.  Moreover, R265H was shown to be able to dimerize with the wild 
type enzyme, giving rise to an enzyme that is unable to synthesize AdoMet, but that hydrolyzes 
tripolyphosphate.  Based on these results, Pérez-Mato et al. [190] suggested that R265H folds 
approximately to MAT!s final structure before association takes place [190]; association then 
could occur in a late intermediate as deduced from the folding data [195, 196].   
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 12.3. MAT and Cancer 
 Cancer is one of the most common causes of death in the first world.  Its basis depends 
on genetic and environmental factors, but in all cases the common outcome is anomalous cell 
growth.  For this to occur, cell cycle deregulation must take place.  Moreover, another common 
property of human cancer cells is their dependence on exogenous methionine for growth, 
whereas normal cells can use Hcy instead [256].  Thus, there is interest in understanding the 
anomalies in the methionine cycle caused by carcinogenesis, as part of a search for 
chemotherapeutic drugs.   
 In this regard, the effects of carcinogens such as 2-acetyl-aminofluorene [257], 
thioacetamide [192, 258], N-2-fluorenylacetamide [259] and 3'-methyl-4-dimethylaminobenzene 
[260] on methionine metabolism have been studied in animal models.  The collected data 
indicate reductions in MAT1A mRNA[257], protein [258, 261] and activity [192, 257, 258], 
whereas increases in these parameters were reported for MAT2A [258, 260, 262].   
 Other lines of research have taken advantage of samples from different types of tumors 
or tumor-derived cell lines [261, 263].  In all the cases, rapid growth has correlated with an 
increase in MAT II protein levels, while a corresponding decrease in MAT I/III occurs [5].  
Moreover, an increase in MAT activity in malignant cells has been reported, using 
measurements at 50-80 µM methionine [5, 264, 265], thus indicating an alteration of the low Km 
forms of the enzyme.  Such an effect was confirmed in colorectal carcinoma samples where 
increases in MAT II protein and activity were observed [266].  Northern blots did not show 
signals for MAT1A mRNA in hepatoma cell lines, a fact that is not due to deletion or gene 
reorganization, but rather to lack of transcription [265].  Samples from cirrhotic patients and 
HCC show reduced MAT1A mRNA levels, while MAT2A is induced only in the carcinoma [267, 
268].  These effects correlate with increases in transcription and low methylation of the MAT2A 
promoter only in cancer [268].  The effect of reduced methylation on the MAT2A promoter has 
been studied using SssI methylation of promoter constructs fused to a luciferase reporter gene, 
followed by transfection of HepG2 cells and AdoMet treatment of transfected cells.  In both 
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cases a reduction in MAT2A promoter activity was observed, while no effect on MAT1A 
promoter was detected [268].  AdoMet treatment was shown to induce MAT2A promoter 
hypermethylation, a mechanism that has been shown to involve binding of histone deacetylase 
and methyl cytosine-binding proteins such as MeCP2 [269, 270].  Comparison of protein binding 
patterns to the MAT2A promoter between normal and malignant tissues has been also carried 
out, and the observed differences were able to explain the transcriptional up-regulation of 
MAT2A in HCC, as is discussed elsewhere in this review [47, 49].   
 The observed changes in MAT expression and activity are reflected in AdoMet levels.  
Thus, in hepatoma cells an increase in AdoMet is observed upon overexpression of MAT I/III 
[271], whereas a decrease is detected upon thioacetamide treatment [272, 273].  Moreover, this 
rise in AdoMet is correlated with a boost of the AdoMet/AdoHcy ratio.  Such effects, together 
with an increase in DNA methylation, can also be observed after AdoMet treatment.  In fact, it 
has been suggested that the reduction in expression of several oncogenes during hepatic 
carcinogenesis may be occur through changes in their DNA methylation [271].  Global DNA 
hypomethylation seems to be a common property of several diseases in which AdoMet levels 
and MAT1A expression are altered [268].  The role of AdoMet in cancer development was 
confirmed when a MAT1A knockout mouse became available [59]; its chronic AdoMet deficiency 
led to the spontaneous appearance of HCC.  Moreover, AdoMet therapy has been shown to be 
efficient in preventing HCC [274], since it inhibits HGF mitogenic activity and accelerates 
resynthesis of I%B, thus blocking NF%B activation of cytokine-stimulated hepatocytes [275].  On 
the other hand, antisense RNA against MAT2A produced cell death either in normal or MAT1A 
overexpressing hepatoma cells [271].  The presence of the regulatory #-subunit makes MAT II 
more susceptible to AdoMet inhibition [36].  MAT2B expression provides a growth advantage to 
human hepatoma cells, its expression being common in cancer and its induction is frequently 
associated with hepatic dysfunction [36].  AdoMet and 5-methylthioadenosine induce apoptosis 
in cancer cells.  This effect is mediated by induction of Bcl-xs and increases in protein 
phosphatase 1 catalytic subunit which would carry out the protein Ser-Arg dephosphorylation 
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needed for alternative Bcl-x splicing [276].  Methionine deprivation imposes a metabolic stress 
that inhibits mitosis and induces cell cycle arrest and apoptosis.  cDNA array analysis indicates 
that several families of transcription factors are affected by this type of stress, among them AP-1 
and NF%B.  These factors are among those known to regulate MAT2A transcription, as 
discussed in Section 2.3.1 [277].   
 The effect of several chemotherapies on methionine metabolism behavior has been also 
studied.  Among them, fenretidine has been shown to counteract both the induction of NF%B 
mRNA and protein levels, as well as the reduction in levels of I%B upon 2-acetylaminofluorene 
administration.  In parallel, the carcinogen induces iNOS while decreasing MAT1A expression 
[257].  NF%B activation is involved in the entry to the G1 phase of cells that are primed to 
proliferate, maintains cells in early G1, and ensures progression throughS phase by 
transcriptional activation of c-Myc and cyclin D1.  On the other hand, AdoMet increases I%B 
synthesis, and hence raises the levels of the NF%B/I%B complexes and reduces MAT I/III 
activity.  In addition, an increase in NO levels may also collaborate by inactivating MAT I/III and 
reducing AdoMet levels.  However NO can also inactivate NF%B [278], and hence lead to a 
more complicated picture.  Resistance to chemotherapy has also been linked to methionine 
metabolism in some cases, probably through epigenetic effects on DNA methylation [279].  In 
others cases, i.e. doxorubicine resistance, overexpression of multidrug resistance gene (MDR) 
is the primary factor involved.   
 Fetal, regenerating and transformed hepatocytes are able to proliferate.  Their 
progression through the mid/late check point at G0/G1 is regulated by growth factors such as 
HGF, insulin, EGF and TGF"; among these HGF has been shown to induce MAT2A [50].  
Moreover, inhibition of the MAPK and PI3K pathways prevents this up-regulation with 
concomitant induction of MAT1A.  Treatment with the growth arrest factor TGF# attenuates 
mitogenesis and MAT2A up-regulation, while inducing MAT1A.  In addition, AdoMet has been 
shown to inhibit HGF induction of cyclin D1 and D2 expression, leading to the suggestion that 
this metabolite is a negative modulator of cell cycle progression [54].  Moreover, samples of 
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human HCC always showed expression of the #-subunit at higher levels than those shown in 
cirrhotic samples [36].  The same is also true for HCC induced by diethylnitrosamine treatment.  
Analysis of expression in several hepatoma cell lines revealed the presence of the #-subunit in 
HepG2, PLC and H3B, but its absence in Huh7.  Expression of MAT2A in cultured hepatocytes 
led to an increase in MAT2B levels.   
 AdoMet inhibits the mitogenic activity of HGF and prevents MAT2A induction.  The 
mitogenic activity of HGF depends on iNOS and on the L-methionine concentration in the 
medium which exerts its effects through its conversion to AdoMet.  A transitory decrease in 
AdoMet may liberate factors such as HGF from its inhibition, thus allowing the proliferative 
response, such as that observed during regeneration, whereas chronic AdoMet reduction would 
lead to malignant degeneration [276].   
 
 12.4. MAT and Ethanol 
 Intragastric ethanol feeding of rats in combination with a high fat diet increased the 
steady-state levels of both MAT1A and MAT2A mRNAs [280].  In the rat model only MAT II 
protein levels rose noticeably, and in concordance MAT activity (measured at 20 µM 
methionine) doubled [280].  Ethanol induction of MAT2A is mediated by TNF" stimulation, which 
exerts its action on the MAT2A promoter through NF%B and AP-1 binding [47].  On the other 
hand, micropigs showed a decrease in total MAT activity upon ethanol feeding (measured at 5 
mM methionine) [281], and MAT1A transcripts decreased under these diets, either combined or 
not with folate deficiency [281].  Reductions in AdoMet levels were observed during ethanol 
feeding of rats [280], baboons [282] and micropigs [281], as well as in patients with alcohol 
hepatitis [283].  However, differences in the effects on AdoHcy levels were observed among the 
models.  Thus, while rat intragastric ethanol feeding produced no change in AdoHcy [280], 
micropigs fed ethanol in combination with a folate deficient diet showed an increase in the levels 
of this metabolite [281].  In both cases the net result is a decrease in the AdoMet/AdoHcy ratio 
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that in rats correlates with a reduction in the global DNA methylation.  In addition, increases in c-
Myc expression and genome-wide DNA strand break accumulation are observed.   
 Alcoholic liver cirrhosis is associated with increased risk of liver cancer [280].  A 
reduction in MAT1A mRNA levels was observed in samples from cirrhotic [267] and alcoholic 
hepatitis patients [283], while MAT2A is not induced.  Hypermethylation of MAT1A promoter 
was also detected.  A high percentage of samples of cirrhotic patients (84%) express the #-
subunit, but no correlation between expression and etiology was established [36].  In addition 
other enzymes of the methionine cycle, such as GNMT, MS, BHMT and CBS have very low 
levels in these patients, the percentage of livers with low or very low levels is higher in HCV 
cirrhosis samples than in alcoholic cirrhosis specimens [267].  Moreover, Hcy can potentiate the 
fibrogenic effects of ethanol by inducing expression of tissue inhibitor metalloproteinase-1 
(TIMP-1) and "1 (I) procollagen [4], and reducing GSH, plasma taurine and urine sulfate levels.  
Thus, defects in Hcy remethylation may contribute to HCC development in cirrhosis [267].   
Cellular levels of AdoMet seem to be related to the differentiation status of the hepatocyte, being 
lower in growing cells [271].   
 Liver damage during short- and long-term ethanol consumption [284-286] has been 
associated with a reduced oxygen supply to this organ.  Sustained hypoxia such as that 
observed in liver cirrhosis and long-term ethanol consumption would induce down-regulation of 
MAT expression; this situation may promote irreversible tissue damage through the impairment 
of methylation reactions, and GSH-dependent detoxification capacity [61].  In this regard, the 
reversible inactivation of MAT regulated by the intracellular levels of GSH and NO [67] may 
exert a fundamental role in the effects derived from ethanol consumption.  Both GSH reduction 
and increases in protein nitrosylation are known to occur in these cases.  Other protein 
modifications, due to products of ethanol catabolism, such as the irreversible covalent binding of 
acetaldehyde to lysine residues, have not been explored yet, and may also be involved in the 
described effects.   
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 The MAT1A knockout mouse displays alterations common to ethanol treatment, such as 
induction of CYP2E1; these effects make it more susceptible to injury (i.e. by CCl4) and 
reduction in GSH levels [59].    
 
 13. Conclusions 
  This review has attempted to provide an overview of the methionine adenosyltransferase 
research, an area that has vastly expanded in the past decade.  Numerous opportunities remain 
before a comprehensive understanding of this unique enzyme is obtained and can be exploited 
for therapeutic purposes.  New crystal structures that clarify the mechanism of the reaction are 
needed, as well as structural data for dimeric and large-molecular weight isoenzymes.  
Moreover, discerning the role of MAT in diseases as complex as hepatoma or Parkinson!s may 
relate, not only to AdoMet synthesis, but also reveal interactions with other pathways that thus 
far remain elusive.   
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Figure legends   
 
Figure 1. A) MAT and AdoMet metabolism  The many ways in which AdoMet is used contrast 
with the single way in which it is formed.; B) The MAT catalyzed reaction illustrating the 
intermediate complex with bound tripolyphosphate (PPPi). 
 
Figure 2.  The methylation cycle in which is predominantly found in mammalian liver. 
 
Figure 3 Schematic representation of MAT promoters. The upper scheme represents 
MAT1A promoter. The elements and DNase protection areas are identified as: +1 indicates the 
transcription initiation site, the TATA box is located at -29/-23, two CAAT box are also indicated. 
Boxes A-D indicate the mocations for positive acting elements, A and B identified in H35 cells 
and C and D in CHO cells. The lower scheme shows the MAT2A promoter, where E-G 
represent SpI sites and H the area of NFkB and AP-1 binding. 
 
Figure 4 A) Ribbon diagram of the monomer of the human MAT II illustrating the near three fold 
symmetry of the fold and the central loop (pdb code 2PO2); B) the tetramer of cMAT (pdb code 
1RL7) in complex formed with AMPPNP and methionine; half of the active sites had bound 
products AdoMet and PPNP.  The active site is buried at a subunit interface. 
 
Figure 5 Active site structures of MATs A) MAT I B in complex with ATP and methionine;  
Mg2+, K+ and Pi are also in the active site (pdb code 1O9T) B) E. coli MAT in complex with 
AMPPNP and methionine; the 2 Mg2+and 1 K+ are not shown (pdb code 1RL7) C) overlay of 
selected regions of the active sites of cMAT and rMAT.  The exchanged orientation of the 
substrates is shown when the protein portion of the structures Is aligned, illustrated by the 
position of the active site histidine. 
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Figure 6 Kinetic Mechanism A) The mechanism for the E. coli  MAT is shown. Other MATs 
prefer to bind ATP first and have different orders of product release. The protein conformational 
change, probably due to loop movement, is shown by the change in font of E to “E”.  B) The free 
energy changes associated with each step are illustrated for physiological concentrations of 
substrates and products; the chemical reaction steps are included in the box. 
 
Figure 7.  Folding pathways for MAT I/III. The figure shows a schematic representation of the 
data available for MAT I/III unfolding. Free energy changes calculated for each step are also 
included. The different intermediates are denoted I, Ik
1 and Ik
2, whereas M represents the 
monomeric mutant R265H, and U the unfolded state.  
 
Figure 8 Structures of selected inhibitors of MATs.  Ki values for various MATs are listed in 
Table 2. 
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TABLE 1 
Enzymatic properties of MAT from different sources. 
 
source Oligomeric 
state 
Km
ATP or 
S0.5  
(µM) 
Km
Met or 
S0.5  
(µM) 
Ki
AdoMet 
(µM) 
Vmax 
(µmol/min/
mg) 
pH optimum reference 
E. coli tetramer 110 80 10 1.2 6-9 [121] 
M. jannaschii dimer 290 240 120 3.0  [152] 
Bakers yeast isozyme 
1 
heterodimer 74 110  0.6  [115] 
Bakers yeast isozyme 
2 
heterodimer 47 140  0.36  [115] 
Rat MAT I* tetramer 252 125   7.5-8.8 [8] 
Rat MAT III* dimer 950 650   7.5-8.8 [8] 
Human MAT II !/" heterotetramer 31 3.3 18 0.2 7-8.5 [29] 
Human MAT II (no ") dimer  80    De La Rosa, 1995 #182}} 
L. infantum dimer 370 PC 250 PC 1500 0.2  [145] 
L. donovanii dimer 27 PC 250 PC 4000 0.2  [146] 
P. falciparum dimer      [148] 
T. brucei brucei mixed 
isoform 
Partial 
purification 
53-1750 
NC 
20-150 
NC 
240  7.5-10 [143] 
* Data for rat MAT I and III refer to the reduced forms obtained after thiopropyl Sepharose purification. 
** C= cooperative; PC= positive cooperativity; NC= negative cooperativity 
 Various assay methods have been used.  Often radioactivity incorporation into AdoMet is measured, which requires separation of 
AdoMet from substrates either by filtration on ion exchange filters or on ion exchange columns.  Phosphate production, either during 
AdoMet formation or in hydrolysis of added PPPi, can also be monitored with purified enzymes.  Much of the variation in literature 
values of kinetic constants can likely be traced to different assay conditions and methods of product determination.  
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Table 2 
Selected Inhibitors of MAT.  
Analogues of the substrates which have been tested as possible MAT inhibitors.  Selected structures are shown in Figure 8. 
The table shows some of the most effective among them. 
Analogue characteristics Ki (µM) references 
Cycloleucine, 1-amino-cyclopentane 
carboxylic acid 
  209-1633 [206] 
1-aminocyclobutane carboxylic acid 1.5-12.4 mM* [206] 
1-aminocyclo-hexane carboxylic acid 
Less potent than cycloleucine 
8.2-57.4 mM* [206] 
(+)- 2-aminobicyclo [2.1.1]-hexane-2-
carboxylic acid 
Ki 2-7 fold lower than cycloleucine 80-680 [206, 287]  
L-2-amino-4-hexynoic acid 1500 [288] 
Z-L-2-amino-5-chloro-trans-4-
hexenoic acid 
As potent as cycloleucine against control 
enzyme or Novikoff hepatoma, and 2-3-fold 
more potent than cycloleucine against 
normal isoenzymes. 
550 [288] 
L-ethionine* 790-15.4 mM* [206] 
S-n-propyl-DL-homocysteine 39-113 mM* [206] 
S-n-butyl-DL-homocysteine 
All of them have lower affinity than 
cycloleucine to the active site. 
* the most potent in this group, also 149-234 mM* [206] 
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Se-DL-ethionine* substrate for normal and tumor isoenzymes, 
as well bacterial MAT 
1.98-11.1 
mM* 
[206] 
L-2-amino-4-methylthio-cis-but-3-
enoic acid 
Less potent than the ether analog due to 
non-planrity of the sulfur with the olefin 
5.7-21 [204] 
L-2-amino-4-methyl-cis-but-3-enoic 
acid 
The most potent methionine analog inhibitor 5.7-21** [204] [289] 
6-(n-Butylthio)-9-[5!(R)-C-(L-
homocystein-S-yl-methyl]-"-D-
ribofunanosyl]purine 5!-",#-
imidotriphosphate 
Bisubstrate analog, selective for tumor 
isozyme 
0.1 – 1.7 [203] [203] 
Diimidotriphosphate slow tight binding intermediate analog; 
tested only with bacterial and archaeal 
enzymes  
 2 nM [211] 
• *The range indicates the lower and higher values for liver MAT isoenzymes. 
• ** Assayed against L1210 murine leukemia cells 
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Table 3 
 
 Mutations of MAT1A detected in individuals with hypermethioninemia 
 
Exon Gene Protein character activity Association 
state 
Liver 
activity 
reference 
C65T S22L HO**    [290]; [255]  
I G113A S38N CHE* none  68% [244], [249] 
T125C L42P HO    [290]; [255] 
C164A A55D CHE    [14] 
G205A G69S     [252] 
 
 
 
 
II 
 
255#CA 92X CHE none   [244], [249] 
III  G98S HO normal   [249] 
C426T  CHE    [14]  
 
V 
539insTG 185X HO, CHE   7% [15], [250] 
 C595T R199C CHE, HO 10%   [15] 
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C745T R249W     [252] 
G791A R264H  <1% monomer low [245, 247], [248, 249], [252] 
G791T R264C CHE none   [249] 
G867A R264C     [252] 
 
 
 
 
 
VI 
 
 
 
 K289N     [252] 
G870A  CHE    [14] 
T914C L305P CHE    [14] 
 
 
 
VII 
827insG 351X HO    [15] 
T966G I322M HO, CHE Low   [14], [249] 
G1006A G336R CHE 23%   [249] 
A1031C E344A CHE low   [249] 
1043,1044del 350X HO    [240], [15] 
G1067A R356Q CHE 53%  low [291], [15] 
 
 
 
 
 
  R356P     [252] 
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VIII 
C1070T P357L CHE    [14],[252] 
T1131C  CHE    [14] 
G1132A G378S CHE 0.1%   [291], [15],[251] 
G1161A W387X CHE, HO 75% dimer  [251] 
 
 
 
IX G1188T X396Yfs
X464 
    [252] 
*CHE, compound heterozygosis 
**HO, homozygosis 
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